

March 2021

**EDISON TAK-BUN LIU, M.D.
CURRICULUM VITAE**

Place of Birth: Hong Kong, China

Citizenship: USA
(Singapore Permanent Residency)

Work Address: The Jackson Laboratory
600 Main Street
Bar Harbor, Maine
04609

Telephone: +207-288-6041 (work)

E-mail: edison.liu@jax.org

Marital Status: Married with three children



Education

Oct. 1969 - June 1973 Stanford University, B.S. Chemistry, Psychology
Oct. 1973 - June 1978 Stanford University, M.D.

Post Graduate Training

July 1978 - July 1979 Internship, Barnes Hospital - Washington University, St. Louis
July 1979 - July 1980 Residency, Barnes Hospital - Washington University, St. Louis
July 1980 - July 1982 Oncology Fellowship, Stanford University
July 1982 - July 1985 Hematology Fellowship, University of California San Francisco, Moffitt Hospital
Dec. 1983 - July 1987 Postdoctoral Fellow - Dept. of Microbiology, University of California at San Francisco, CA (Dr. J. Michael Bishop)

Appointment History

Jul 1985 - Jun 1987 Instructor, Department of Medicine, Division of Oncology (University of California at San Francisco)
Jul 1987 - Jun 1993 Assistant Professor in Medicine and Oncology, School of Medicine University of North Carolina at Chapel Hill
Jan 1988 - Jul 1993 Director Preleukemic Clinic, North Carolina Memorial Hospital, UNC Chapel Hill

Jan 1988 - Sept 1996	Faculty, Curriculum in Genetics, University of North Carolina at Chapel Hill
Jul 1989 - Jun 1991	Director, Hematology/Oncology Training Program, University of North Carolina at Chapel Hill
Aug 1989 - Jul 1992	Director, DNA Tumor Bank, Lineberger Cancer Research Center, UNC Chapel Hill
Jul 1992 - Sept 1996	Co-Director: Laboratory of Molecular Epidemiology, UNC Chapel Hill, School of Public Health
Feb 1993 -Sept 1996	Leader, Breast Cancer Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Jul 1993 - Aug 1995	Associate Professor, Department of Epidemiology, University of North Carolina at Chapel Hill
Jul 1993 - Aug 1995	Associate Professor, Department of Medicine, University of North Carolina at Chapel Hill
Jul 1993 - Sept 1996	Chair, Solid Tumor Correlative Sciences Committee; Cancer and Leukemia Group B
Sept 1992- Sept 1996	Director, Specialized Program of Research Excellence in Breast Cancer (NIH Designated). UNC Chapel Hill
Aug 1995 - Sept 1996	Faculty, Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill.
Aug 1995 - Sept 1996	Professor, Departments of Medicine, Epidemiology, Biochemistry and Biophysics. UNC Chapel Hill
Dec 1995 -Sept 1996	Chief, Division of Medical Genetics, University of North Carolina at Chapel Hill School of Medicine
Mar 1996 - Sept 1996	Member, Board of Scientific Advisors, National Cancer Institute
Sept 1996 – Mar 2001	Director, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD
Jun 1997 – Mar 2001	Chief, Molecular Signaling and Oncogenesis Section, Department of Cell and Cancer Biology, Medicine Branch, Division of Clinical Sciences, National Cancer Institute
March 2001 – December 2011	Executive Director, Genome Institute of Singapore
March 2001 – present	Professor of Medicine, Yong Loo Lin School of Medicine. National University of Singapore (until 2017),
March 2001 – May 2008	Special Advisor to the President, National University of Singapore
November 2001 – present	Professor, Department of Epidemiology and Public Health, National University of Singapore
May 2002 – November 2009	Executive Director, Singapore Tissue Network (National DNA Repository)
February 2003 – February 2008	Executive Director, Singapore Cancer Syndicate (a funding agency)
January 2005 – present	Adjunct Professor of Molecular and Cellular Biology at University of Illinois, Urbana-Champaign
2005 – 2008	Visiting Scientist. RIKEN Institute. Japan
November 2006 – 2008	Adjunct Professor of Johns Hopkins Division of Molecular Medicine Department of Medicine

2009 – 2011	Adjunct Professor, Nanyang Technology University (Singapore)
2010 – present	Honorary Joint Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore
January 2012 - present	President and CEO, The Jackson Laboratory
January 2013 – present	Professor in the Department of Genetics and Developmental Biology, University of Connecticut Health Center
January 2013 – present	Director, The Jackson Laboratory Cancer Center (NCI Designated)

Current Position

President and CEO, The Jackson Laboratory

The Jackson Laboratory, established in 1929, is the key institution for mouse genetics that has 2,000 full time employees, 68 Principal Investigators now in three campuses (Maine, California, and Connecticut). The annual operating budget is \$500 million dollars (2020). In 2011, the State of Connecticut appropriated \$291 million for the building of a 175,000 sq ft building for the Jackson Laboratory. The President is responsible for the operations, recruitment, and strategy for the institution. In the last nine years, we have increased the operating budget by 100%, doubled the faculty, entered into translational and clinical sciences, and expanded our physical footprint to include four campuses in three states, and initiated a business component in China. In the process, The Jackson Laboratory moved from a singular focus on mouse genetics to becoming a national center for complex genetics and functional genomics using the mouse and the human as model systems.

Director, The Jackson Laboratory Cancer Center

The Jackson Laboratory is an NCI designated basic cancer center in its 28⁺ year. As its Director, I successfully took the cancer center through two successful competitive renewals in 2014 and 2019. We have expanded the cancer center to 52 members (of 71 faculty) and have increased our NCI funding by 3-fold. We now have an impactful presence in translational cancer medicine and are engaged in genomic diagnostics and therapeutics. Our strategy is to focus on “precision models for cancer biology” and to use cutting edge technologies to attack problems in cancer biology and therapeutics.

Previous Executive Positions

President, Human Genome Organization (HUGO)(June 2007 – May 2013)

HUGO is the professional organization of genomicists and geneticists involved in the science of the human genome. The Presidency is a 3 year term and is elected by the HUGO Council. Upon election in summer of 2007, I moved to balance the finances of the organization, moved the office from London to Singapore, and to reinvigorate the mission and focus of HUGO towards Genomic Medicine and to realize the aspirations of emerging countries. In my presidency, I have initiated a new journal for HUGO in collaboration with Springer Publishing Group (HUGO Journal), established the HUGO Pan Asian SNP Initiative, launched new formats in workshops and the annual HGM meetings, and formulated new international collaborative links in Asia, South America, and the Middle East.

Executive Director, Genome Institute of Singapore (GIS) (2001-2012)

The Genome Institute of Singapore is to establish the academic framework for genomic resources in Singapore; to conduct cutting edge genomic science; to provide the infrastructure and training in

genomics for Singapore and the region; and to attract R&D ventures in biomedicine into Singapore. As the founding director, I built the institute from 3 individuals to the current 280 staff members covering the areas of genomic technologies, computational biology, population genetics, and cell biology. The executive director has jurisdiction over budget, space, recruitment, and scientific direction. Moreover, the executive director is a senior advisor to the Singapore government for matters pertinent to genomic sciences, including educational reform, and pandemic response.

Chairman, Governing Board, Health Sciences Authority of Singapore (HSA)(February 2007-2011)

The HSA is the major health regulatory authority for Singapore responsible for pharmaceutical regulation, national blood banking, and forensics. Therefore, the HSA is the US FDA, Red Cross, and FBI Forensics Laboratory inclusive. As a statutory board, the HSA is managed by a CEO, and governed by a board comprising scientific, medical, governmental, business leaders. The chairman of the HSA board is responsible for conduct of the governing board whose responsibilities include strategic and financial oversight, approvals of key appointments, and major policy positions. In this capacity, I have initiated with the CEO a number of sweeping changes regarding drug approval processes, organizational structure, human resource management, and the establishment of a research academy within the HSA.

Founding Executive Director, Singapore Cancer Syndicate (2003-2008)

The Singapore Cancer Syndicate (SCS) is a unique funding agency that seeks to coordinate and empower translational cancer research in Singapore. S\$75 Million was allocated for five years (2003-2008) to fund in a managed fashion, the hardening of the infrastructure that supports the clinical translational research pipeline of the country. The SCS is supporting cancer clinical trials groups, molecular pathology, bone marrow transplantation, GMP facilities, biomarker discovery, and pharmacokinetics and pharmacodynamics units. All funded groups have milestones which were the criteria for continued funding. This initiating funding mechanism spawned an expansion of cancer related funding nationally to ~300 million dollars. At the end of the 5 year funding (2003-2008), the cancer syndicate, having successfully completed its mission, was closed.

Founding Executive Director, Singapore Tissue Network (2002-2009)

As the founding director of the Singapore Tissue Network, I conceived and established the first national tissue and DNA bank for Singapore. I recruited staff, arranged training, and established governance and policies. To date, the STN holds over 40,000 tissue entries, and is the major national repository for DNA and serum. It has participated in national deliberations over ethical guidelines for genetic research, and tissue procurement policies.

Director of the Division of Clinical Sciences, NCI (1996-2001)

The National Cancer Institute has three intramural divisions that conduct research at the Maryland campus of the NIH: Clinical Sciences, Basic Sciences, and Cancer Epidemiology and Genetics. The Division of Clinical Sciences has a total of 1,200 employees organized in 16 branches/laboratories/departments, and include 100 principal investigators, 40 staff clinicians, and approximately 360 M.D. and Ph.D. trainees, as well as pre- to post-baccalaureate level individuals. The DCS is responsible for the clinical and clinical translational research for the NCI intramural program, and conducts investigations spanning basic laboratory research to clinical trials, and epidemiologic studies. The Division Director has jurisdiction over budget, personnel, space management, scientific initiatives and scientific review within their divisions.

Chairman, Solid Tumor Correlative Sciences Committee; Cancer and Leukemia Group B (CALGB) (1993 – 1996)

In the US, cancer phase II and III clinical trials are conducted by NCI funded National Cooperative Groups. CALGB was one of the major cancer clinical cooperative groups that organized clinical trials over all cancer types. In 1993, I was asked to initiate a working committee to coordinate all clinical translational scientific work in solid tumors for the cooperative group. My responsibilities were to organize and lead the molecular translational sciences for this national cooperative clinical trials group in oncology in solid tumors. In this position, I formulated the review process, and coordinated the execution of the plans. I was the PI or co-PI in competitive national cooperative translational network grants (U01 and U10 mechanisms) for the CALGB to fund these efforts.

Director/Principal Investigator, Specialized Programme of Research Excellence in Breast Cancer (NCI) (1992-1996)

In 1991, the NCI embarked on a new large scale programme to focus on integrated translational sciences targeting specific cancers. At that time, the allowable direct cost of \$1.5 million USD per year for a research programme was unique and rivaled the cancer center programme. I led the proposal from the University of North Carolina, Chapel Hill focusing on Molecular Epidemiology of breast cancer and was the one of the first three recipients of this new grant mechanism. As Principal Investigator, I had fiscal and scientific responsibility over the University programme, talent recruitment, and was the primary liaison with the National Cancer Institute.

Board Certification

Internal Medicine - Certified 1983

Hematology - Certified 1984

Oncology - Certified 1985

Professional Licensure

California - G42337 (inactive status)

Missouri - R1A59 (inactive since 1991)

North Carolina – 15208 (inactive status)

Professional Organizations

American Society for Clinical Investigation (elected)

Cancer and Leukemia Group B: Chair, Solid Tumor Correlative Sciences Committee (resigned 1996)

Human Genome Organization (HUGO)

Southwest Oncology Group

Association of American Cancer Institutes

American Society of Human Genetics

American Association for Cancer Research

Special Honors and Awards

1972 June-Sept.	National Science Foundation Fellowship in Chemistry 1972: To study the photoconversion of aziridines to ethylene for its agriculture applications. Preceptor: Dr. J. D. White
1973 June	Phi Beta Kappa, Stanford University
1974 July-Sept.	Ford Foundation Fellowship for Intensive Studies in Chinese, Stanford University

1983-1985	Damon Runyan Cancer Fund Fellowship Preceptor: Dr. J. Michael Bishop (UCSF)
1985-1988	Clinical Investigator Award, National Cancer Institute, K08-CA01036-02, Preceptor: Dr. J. Michael Bishop.
1990-1994	Jefferson Pilot Award: University of North Carolina at Chapel Hill, Junior Faculty Award for Research Excellence
1991-1996	Leukemia Society Scholar
1995 July	American Society of Clinical Investigation (<u>Elected</u> Membership)
1996 October	1996 Brinker International Award for Breast Cancer Research - Basic Research Award
1999-2001	<u>Elected</u> -Board of Directors, American Association for Cancer Research
2000 April	Rosenthal Award, AACR: for the discovery that HER-2 status determines response to adjuvant chemotherapy with doxorubicin.
September 2003	Public Service Medal (National Day, 2003): for work in controlling SARS in Singapore (given by the Office of the President, Republic of Singapore)
2007-2010	<u>Elected</u> – President, Human Genome Organization (HUGO)
2007 July	Awarded Doctor of Medical Sciences honoris causa, Queen's University, Belfast
2008 September	<u>Elected</u> , Foreign Associate Member, European Molecular Biology Organization (EMBO)
2010-2013	<u>Re-elected</u> - President, Human Genome Organization (HUGO)
2010 October	Fellow of the Hastings Center (New York, Elected Membership)
2013 January	<u>Elected</u> , Fellow of the Connecticut Academy of Sciences and Engineering
2014 April	2014 Chen Award for Distinguished Academic Achievement in Human Genetic and Genomic Research (from the Human Genome Organization)
2016 May	Awarded Doctor of Sciences honoris causa, Colby College, Waterville, Maine
2016 November	<u>Elected</u> , American Association for the Advancement of Science (AAAS) Fellow
2017	50 th Anniversary Founding of the Republic of Singapore- Announced: One of 50 most important foreigners in Singapore's history
2018-present	<u>Elected</u> , Board of Directors, American Association for Cancer Research

Editorial Boards (bold = current appointments)

BMC Genomics: Editorial Board (2005-present)

Breast Cancer Research (Current Opinions): Associate Editor (2001 -2012)

Breast Cancer Treatment and Research: Associate Editor

Breast Disease: Editor-in-Chief (1999 - 2007)

Breast: Editorial Board (completed 1999)

Cancer Letters (Completed 2002)

Cancer Therapeutics (Completed 1999)

Clinical Cancer Research: Associate Editor (2001- 2012)

Current Cancer Drug Targets (completed 2002)
 Current Opinion in Oncology (2005-2009)
 Encyclopedia of Diagnostic Genomics and Proteomics (2002-2010)
 Faculty of 1000, contributing faculty (Physiogenomics) (2005-2006)
Genome Biology (2001-present)
 Genomic Medicine (2007-2009)
 Journal of Clinical Oncology (completed 1998)
 Journal of Mammary Gland Biology and Neoplasia (1999 - 2006)
Journal of Translational Medicine (2003-present)
Lancet Oncology (2005-present)
 Leukemia: Editorial Board (completed 1996)
Molecular Cancer Therapeutics (2001-present)
Molecular Oncology (2006-present)
Molecular Systems Biology: Senior Editor (2004 - present)
 Public Library of Science: Biology (2003-2012)
 Public Library of Science: Computational Biology (2005-2012)
 Public Library of Science: Medicine (2004 - 2011)
Wiley Interdisciplinary Reviews (WIREs): Systems Biology: Editorial Board (2006 - present)
 The HUGO Journal: Editor-in-Chief and Founding Editor (2009-2013)
EMBO Molecular Medicine: Editorial Board (2008-present)
Human Genetics: Editorial Board (2009-present)
JAMA Oncology: Editorial Board (2014-present)

Institutional Committees and Working Groups (at time of affiliation)

1995-1996	National Action Plan on Breast Cancer - Biological Resources Working Group
1996	Lineberger Cancer Center Advisory Committee: Clinical Cancer Program
1996	Protocol Review and Monitoring Committee, NCI
1996-1997	NIH Committee on the Recruitment and Career Development of Clinical Investigators
1996	NCI - Developmental Diagnostics Working Group, 1996
1996	NCI - Cancer Genetics Working Group, 1996
1996	NCI - Clinical Trials Working Group, 1996
1996	American ACR - Clinical Cancer Research Committee, 1996
1997	SBRS Policy Board, NIH
1997	Molecular Epidemiology Coordinating Group, NCI
1997	Chairman, NIH Committee on Extramural/Intramural Investigations in the Clinical Center
1997-2001	Co-Chair, NIH Clinical Center Advisory Council
1997-2001	NIH Clinical Research Revitalization Committee
1997-1998	NCI Breast Cancer Program Review Group
1998-2001	NIH Building 10 Revitalization Committee
1999-2001	NIH Committee to establish NIH graduate program
2001-2003	University Promotion and Tenuring Committee (National University of Singapore)
2001	President's Life Sciences Committee (National University of Singapore)
2002	National University of Singapore: Feasibility study team for the establishment of a multicampus university.
2002	Biomedical Sciences Executive Committee, A*STAR (Singapore)
2004	Member, Search Committee for Deputy President (Research & Technology, NUS)
2009	Chairman, Search Committee for the Dean, College of Sciences, Nanyang

National and International Committees and Boards (Non-Profit, Scientific, or Governmental)

Policy Setting Boards:

2000-2001	NCI-Ireland-Northern Ireland Cancer Consortium Governing Board (Founding member)
2000	American Association for Cancer Research, Clinical Cancer Research Committee
2000-2002	American Association for Cancer Research, Board of Directors (elected)
2002-2008	American Association for Cancer Research, AACR International Affairs Committee
2002-2004	National Health Group, Clinical Research Advisory Committee (Singapore), Committee Chairman This committee restructured the clinical research framework for half of Singapore's health care delivery system
2003	International Genetics Federation Board of Advisors
2003-2007	Bioethics Advisory Committee (member), Singapore Advisory to the Cabinet of Singaporean Parliament
2001-2003	Genetically Modified Organisms Advisory Council (Singapore Government)
2002	Ministerial committee to reevaluate Singapore's secondary school system (Ministry of Education, Singapore)
2004-2005	University Autonomy, Governance, and Funding Steering Committee (Ministry of Education Singapore, member)
2004-2009	Chairman , Research Policy & Review Committee, National Health Group, Singapore (Management and oversight of the clinical research for half of Singapore's health care delivery system)
2005-present	AACR International Affairs Committee (member)
2006 – 2008	Council Member of the Board of National Medical Research Council (NMRC), Singapore
2007-2009	International Regulome Consortium. Steering Committee (member)
2007-2010	International Cancer Genomics Consortium. Steering Committee (observer member)
2009–2013	Academy of Medical Sciences (UK), International Committee (member)
2010-2013	Global Agenda Council on Genetics, World Economic Forum (member)
2012	American Society of Human Genetics, Nominating Committee (elected)

Governing Boards:

2000-2002	American Association for Cancer Research, <u>Board of Directors</u> (elected)
2003-2008	National Graduate School (NUS) <u>Governing Board</u> .
2004	Singapore American School (SAS) <u>Board of Governors</u>
2006- 2008	<u>Governing Board</u> , National Health Group (member) NHG provides one half of Singapore's health care delivery system
2005-2008	NUS High School of Math and Sciences (Singapore), <u>Board of Governors</u> (Member)
2005-present	NUS-Duke Graduate Medical School (Singapore), <u>Board of Directors</u> (Member).
2006-present	Human Genome Organization (HUGO) Council (elected member)
2006 – 2007	<u>Governing Board</u> , Health Sciences Authority (FDA equivalent of Singapore) Deputy Chairman
2006 - 2008	AACR Nominating Committee (elected member)
2007 – 2011	Chairman , Governing Board Health Sciences Authority of Singapore (FDA equivalent for Singapore)
2007 - 2010	Elected, President , Human Genome Organization
2008 – 2010	Member of the <u>Governing Board</u> of National Medical Research Council (NMRC)
2008 - 2012	<u>Board of Governors</u> , Duke-NUS School of Medicine

2008 - 2012 Board of Trustees member, National University of Singapore
 2009 - 2014 Keystone Symposia Governing Board, and Committee on Globalization.
 2010 - 2013 Re-elected, **President**, Human Genome Organization
 2013-**present** Council member, Human Genome Organization
 2012 - 2015 Board of Directors, Association of American Cancer Institutes
 2012-**present** Board of Directors, Foundation for the National Institutes of Health
 2018-**present** American Association for Cancer Research, Board of Directors (elected)
 2020-**present** American Cancer Society, Board of Directors

Operational Committees for Cooperative Groups:

1993 - 1996 **Chairman**, Solid Tumor Correlative Sciences Committee;
 Cancer and Leukemia Group B

My responsibilities were to organize and lead the molecular translational sciences for
 this national cooperative clinical trials group in oncology in solid tumors.

2015 – present Member, Southwest Oncology Group, Translational Sciences Committee

Advisory Boards

1994 University of California at San Diego. San Diego, CA
 External Advisor for the Cancer Center
 1995 University of Texas at Dallas, Southwestern. Dallas, TX.
 External Advisor for the Cancer Center
 1995 Dartmouth University, Norris Cotton Cancer Center, New Hampshire.
 External Advisor for the Cancer Center
 1995 University of Colorado at Denver External Advisor for breast cancer program.
 1995 City of Hope, Duarte, California External Advisor, Breast Cancer Program
 1996-1999 Susan G. Komen Breast Cancer Foundation External Advisor
 1998-2001 Breast Cancer Research Foundation, New York Scientific Advisory Board
 1998-2000 Asian American Women's Cancer Coalition, San Francisco Advisory Board
 2001 IBM, Blue Gene. External Advisory Board
 2001 Moffitt Cancer Center, USF. Advisory Board 2001
 2002-2005 Institute of Molecular Biology. University of Queensland (Brisbane, Australia).
 Board of Scientific Advisors
 2002-2007 National Center of Competence in Research (NCCR, Australia). Scientific Advisory
 Board.
 2003-2007 Ngee Ann Polytechnic Biotechnology Advisory Board
 2004 FANTOM3 working group member (Riken, Japan).
 2005 – 2006 Johns Hopkins Singapore, **Chairman**, Scientific Advisory Board.
 2006- 2010 American Association for Cancer Research. Scientific Advisory Council.
 2007- 2018 Scientific Advisory Board Member. Finnish Institute for Molecular Medicine
 2007- 2013 Keystone Symposia Scientific Advisory Board. Member
 2008 –2012 Scientific Advisory Board Member, Cold Spring Harbor Laboratory Conferences
 Asia
 2009-2013 Keystone Symposia Governing Board. Member
 2009-2012 Keystone Symposia Globalization Committee. **Chairman**
 2010-**present** International Advisory Board, National Institute of Biomedical Genomics. Kolkata,
 India
 2011 World Health Organization, "Grand Challenges in Genomics for Public Health in

Developing Countries"

2010-2013 Scientific Advisory Council, Archon X Prize in Genomics

2011-**present** Scientific Advisory Board, Philippines Genomic Center

2011-2015 Chinese University of Hong Kong, Scientific Advisory Committee to the Dean (HK SAR)

2012-**present** Scientific Advisory Board, Institute for Systems Genomics, University of Illinois at Champaign Urbana.

2013-2015 Board of Directors, American Association of Cancer Institutes

2013-**present** Board of Directors, Foundation for the NIH

2014-**present** External Advisory Council, Purdue University Cancer Center, West Lafayette, IN.

2016-**present** **Chairman**, Scientific Advisory Board, Sidra Medical and Research Center, Qatar

2017-**present** **Chairman**, External Advisory Board, University of Illinois Urbana Champaign Cancer Center

2018-**present** External Advisory Board, University of Arizona Cancer Center

Awards Committees:

1998-1999 General Motors Cancer Research Awards Committee: Mott Award (USA)

1999-2000 Chair, General Motors Cancer Research Awards Committee: Mott Award

2002-2006 General Motors Award, General Assembly (USA)

Consultation Activities, Membership on Company Scientific Boards

- Clontech, Inc., Palo Alto, Ca. (1987-1990) Consulted on development of Ras-mutalyzer product.
- Amgen, Corp., Thousand Oaks, CA (1991-1994) Consultant on the development of the AXL ligand as a therapeutic.
- Ciba-Corning/Chiron Consultant on Oncogene Diagnostics, 1995
- Xanathon Inc., North Carolina Scientific Board, 1997-2000
- Vysis. Scientific Advisory Board. 2001-2002
- S*Bio, Singapore. Scientific Advisory Board. 2002-2009
- Lilly Systems Biology, Pte. Lt. (Singapore) Scientific Advisory Board 2002- 2007.
- Lilly Singapore Center for Drug Discovery. Scientific Advisory Board. 2007-2010
- Veracyte, Inc. (California) Scientific Advisory Board (2008 – **present**)
- Thermo Fisher Scientific, Inc., Scientific Advisory Board (2012 – 2019)

Patents:

Publication # US5,468,634A DWPI Title: DNA encoding mammalian AXL receptor having tyrosine kinase activity useful in diagnosis and treatment of tumors (1995)

Publication # US6,015,893 Title: Oligonucleoside compounds and methods for inhibiting tumor growth, invasion and metastasis (FAK) (2000)

Publication # US6,531,296B1 DWPI Title: New Rak peptide for use for treating cancer and other neoplastic conditions or non-cancerous diseases (2003)

Publication # US 2005/0095592A1 Title: Classifying an ovarian tumor as a BRCA1 like or BRCA2 like or non-BRCA like tumor by determining a pattern of expression in the ovarian tumor of several markers (2005)

Publication # US2007/0111268A1 Title: Assessing estrogen receptor-beta function determining the level of a marker selected from CDC2, CDC6, DNA2L, CKS2, or using the level of marker as an indication of ER-beta function. (2006)

Publication # WO2010/101528A1 Title: Analyzing cell expression profile for determining metastatic cell, by measuring Jumonji domain containing- nucleic acid or polypeptide in sample of cell with normal non-cancerous cells. (2010)

Publication # WO2009/054806A1 Title: New isolated fused gene comprises first gene and fragment fused to second gene useful for diagnosing and prognosing presence and stage of tumor in a subject (2009)

Publications (refereed)

1. **Liu E**, Rubenstein M. Removal of phenytoin by plasmapheresis in a patient with thrombocytopenic purpura. *Clin Phar Ther* 31(6):762-765, 1982.
2. **Liu E**, Bristow MR, Stone MJ, Willerson JT. Serum Myoglobin, ionized calcium, and parathyroid function during rhabdomyolysis. *Arch Intern Med* 143:154-157, 1983.
3. Schneider PA, Rayner AA, Linker CA, Shuman MA, **Liu ET**, Hohn DC. The role of splenectomy in multimodality treatment of TTP. *Ann Surg* 202(3):318-322, 1985.
4. Connors JM, Andiman WA, Howarth CB, **Liu E**, Merigan T, Savage ME, Jacobs C. Treatment of Nasopharyngeal Carcinoma with Human Leukocyte Interferon. *Journal of Clinical Oncology* 3(6):813-817, 1985.
5. Cadman E, Wong D, **Liu E**. Drug resistance genes can be spontaneously transferred among mammalian cells. *Progress in Clinical and Biological Research: Cancer Drug Resistance*. Editor: Thomas C. Hall 223:11-20, 1986.
6. **Liu E**, Linker C, Shuman M. Management of treatment failures in TTP. *American Journal of Hematology* 23:347-361, 1986.
7. **Liu E**, Hjelle B, Morgan R, Hecht F, Bishop JM. Mutations of the Kirsten-ras proto-oncogene in human preleukemia. *Nature* 330:186-188, 1987.
8. **Liu E**, Hjelle B, Bishop JM. Transforming genes in Chronic Myelogenous Leukemia. *Proc. Natl. Acad. Sci. USA* 85:1952-1956, 1988.
9. Hjelle B, **Liu E**, Bishop JM. The Oncogene v-src transforms and establishes embryonic rodent fibroblasts but not diploid human fibroblasts. *Proc. Natl. Acad. Sci. USA* 85:4355-4359, 1988.
10. **Liu E**, Dollbaum C, Scott G, Rochlitz C, Benz C, Smith H. Molecular lesions involved in the progression of human breast cancer. *Oncogene* 3:323-327, 1988.
11. Santos G, Lee B, **Liu E**, Benz C. Modulation of endogenous c-myc levels in a human mammary carcinoma cell line after estrogen stimulation. *J. Biol. Chem.* 263: 9565-9568, 1988.
12. Wong D, **Liu E**, Cadman E. The enhanced transfer of drug resistance genes in NIH 3T3 cells transformed by the EJras oncogene. *Yale J. Biol. Med.* 61(1):1-10, 1988.
13. Chen L, O'Bryan J, Smith HS, **Liu E**. Isolation of a Matrix Gla Protein in breast carcinoma cells by differential cDNA cloning. *Oncogene* 5(9):1391-1396, 1990.
14. **Liu E**, Santos G, Osborne K, Lee B, Benz C. Overexpression of the c-myc proto-oncogene reduces the growth rate of MCF-7 cells. *Oncogene* 4: 979-984, 1989.
15. Rochlitz CF, Scott GK, Dodson J, **Liu E**, Dollbaum C, Smith HS, and Benz CC. Activating mutations in ras oncogenes associated with primary and metastatic human breast cancer. *Cancer Research* 49:357-360, 1989.

16. Nelson P, Frye RA, **Liu E**. Bifunctional oligonucleotides synthesized using a novel MF-CPG support can detect single base substitutions in genomic DNA. *Nucl Acid Res* 17(18):7187-7194, 1989.
17. Frye RA, Benz CC, **Liu E**. Detection of amplified oncogenes in breast carcinoma using differential polymerase chain reaction. *Oncogene* 4:1153-1157, 1989.
18. Cogswell P, Morgan R, Dunn M, Neubauer A, Poland-Johnston NK, Nelson P, Sandberg AA, **Liu E**. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high incidence of ras mutations in bcr/abl rearrangement negative chronic myelogenous leukemia. *Blood* 74(8):2629-2633, 1989.
19. Ball ED, Mills LE, Neubauer A, **Liu E**. Detection of minimal acute myeloid leukemia cells in bone marrow by probing for mutated ras oncogenes using the polymerase chain reaction and oligomeric DNA probes. *Progress in Clinical and Biological Research*, 333:499-506, 1990.
20. Neubauer A, Neubauer B, **Liu E**. A polymerase chain reaction based assay to detect allelic loss in human DNA: loss of the beta-interferon gene in chronic myelogenous leukemia. *Nucl Acid Res*. 18:993-998, 1990.
21. Neubauer A, Shannon K, **Liu E**. Mutations of the ras prot-oncogenes in childhood monosomy 7. *Blood* 77(3):594-598, 1991.
22. Chen LC, Neubauer A, Kurisu W, Walfman F, Ljung B, Goodson W, Goldman E, Moore D, Balazs M., **Liu E**, Mayall B, Smith HS. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. *Proc. Natl. Acad. Sci. (USA)* 88:3847-3851, 1991.
23. O'Bryan J, Frye RA, Cogswell P, Kitch B, Neubauer A, Espinosa R, LeBeau M, Prokop C, Earp HS, **Liu E**. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. *Mol Cell Biol*. 11:5016-5031, 1991.
24. Smith HS, Stern R, **Liu E**, Benz CC. Early and late events in the development of breast cancer. In *Boundaries between Promotion and Progression during Carcinogenesis*. Ed. Sudilovsky O., et al. Plenum Press, New York, pp. 329-340, 1991.
25. **Liu ET**, Sandler D, Neubauer A, Taylor J, Dodge R, Shore D, Ball E, McIntyre R, Bloomfield CD. Clinical and etiologic importance of mutant ras genes in adult acute myeloid leukemia (AML). *Blood* 78(10), Suppl1:1340, 1991.
26. Effert P, Neubauer A, Walther PJ, **Liu E**. Alterations of the p53 gene is involved in the progression of human prostate carcinomas. *J.of Urology* 147:789-793, 1992.
27. Neubauer A, He Mei, Neubauer B, Effert P, Iglehart D, **Liu E**. Differential Polymerase Chain Reaction in the Analysis of Archival Tissues. *Oncogene* 7:1019-1025, 1992.
28. **Liu E**, He M, Barcos M, Thor A, Benz CC. High frequency of HER-2/neu amplification in in situ carcinoma of the breast: Analysis using differential polymerase chain reaction. *Oncogene* 7: 1027-1032, 1992.
29. Taylor JA, Li Yu, You M, Wilcox AJ, **Liu ET**. B Region Variant of the Estrogen Receptor Gene. *Nucl. Acids. Res*. 20:2895, 1992.
30. Weiner J, Effert P, **Liu E**, Walther P. Human papilloma virus in penile carcinoma: analysis of archival tissues by differential polymerase chain reaction. *Int. J. Cancer* 50: 694-701, 1992.
31. Taylor J, Sandler D, Bloomfield CD, Shore D, Ball ED, Neubauer A, McIntyre RO, **Liu E**. Ras oncogene activation and occupational exposures in AML. *JNCI* 84:1626-1632, 1992.

32. Effert P, McCoy R, Abdel-Hamid M, Flynn K, Zhang Q, Busson P, Tursz T, **Liu E**, Raab-Traub N. Alterations of the p53 gene in Nasopharyngeal Carcinoma. *J Virol* 66:3768-3775, 1992.
33. Effert P, Frye RA, Neubauer A, **Liu E**, Walther PJ. Human papilloma virus subtypes 16 and 18 are not involved in human prostate carcinogenesis: analysis of archival human prostate cancer specimens by differential PCR. *J of Urology* 147:192-196, 1992.
34. Levedakou E, **Liu ET**. Expression of Matrix Gla Protein in Genitourinary Tumors. *Int J Cancer* 52:534-537, 1992.
35. Weiner JS, **Liu ET**, Walther PJ. Oncogenic Human Papilloma Virus Type 16 is Associated With Squamous Cell Cancer of the Male Urethra. *Cancer Research* 52:5018-5023, 1992.
36. Cance, W., Craven, R., **Liu, E.T**. Expression PCR: a sensitive method for analysis of gene expression in human tumors. *Surgical Oncology* 1(4):309-314, 1992.
37. Taylor JA, Wilcox AJ, Bowes WA, Li Y, **Liu ET**, You M. A Common Risk of miscarriage and a common variant of the estrogen receptor gene. *American J of Epidemiology*, 137(12):1361-1364, 1993.
38. Neubauer A, He M, Schmidt C, Huhn D, **Liu E**. Genetic alterations of the P53 gene in CML blast crisis: analysis using PCR based techniques. *Leukemia* 7(4):593-600, 1993.
39. Effert, PJ, McCoy RH, Walther PJ, **Liu ET**. 53 Gene Alterations in Human Prostate Carcinoma. *J. Urology* 150:257-261, 1993.
40. Cance W, Craven R, **Liu E**. Novel kinases expressed in human breast cancer cells. *International J. of Cancer* 54:571-577, 1993.
41. Augustine K, **Liu E**, Sadler T. Antisense inhibition of wnt-1 expression in mouse embryos results in hindbrain, cardiac, and facial abnormalities. *Developmental Genetics* 14:500-520, 1993.
42. Weiner T, Craven J, **Liu ET**, Cance WG. Expression of Focal Adhesion Kinase gene and invasive cancer. *Lancet* 342:1025, 1993.
43. Neubauer A, O'Bryan JP, Fiebler A, Schmidt C, Huhn D, **Liu ET**. Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia. *Semin Hematol.* 30(3 Suppl 3):34, 1993.
44. Muss H, Thor A, Kute T, **Liu ET**, Koerner R, Berry D, Cirrincione C, Wood S, Barcos M, Hendersen CI. c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node positive early breast cancer. *New Engl J Med* 330:1260-1266, 1994.
45. Neubauer A, Dodge R, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloomfield CD, **Liu ET**. Prognostic Importance in the ras proto-oncogene in de novo acute myeloid leukemia. *Blood* 83: 1603-1611, 1994.
46. Neubauer A, Greenberg P, Negrin R, Ginzton N, **Liu E**. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. *Leukemia* 8(4):638-641, 1994.
47. Levedakou E, He M, Baptist E, Craven R, Cance WG, Welch PL, Simmons A, Naylor SL, Leach RL, Lewis TB, Bowcock A, and **Liu ET**. Two novel human serine/threonine kinases with homologies to the cell cycle regulating *Xenopus* MO15, and NIMA kinases: cloning and characterization of their expression pattern. *Oncogene* 9: 1977-1988, 1994.
48. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, **Liu ET**, Ihle JN. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. *Nature* 370:153-157, 1994.

49. Neubauer A, Fiebler A, Graham DK, O'Bryan JP, Schmidt CA, Huhn D, **Liu ET**. The Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. *Blood* 84(6):1931-1941, 1994.
50. McCloskey P, Pierce J, Koski R, Varnum B, **Liu ET**. Activation of the axl receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. *Cell Growth and Differentiation* 5:1105-1117, 1994.
51. Schmidt CA, Neubauer A, Seegar KH, Rochlitz CF, Binder T, Oettle H, Henze G, **Liu ET**, Huhn D, Siegert W. Detection of allelic loss within the beta 1-interferon gene in childhood acute lymphoblastic leukemia using differential PCR. *Ann. Hematol.* 68(4):171-174, 1994.
52. Neubauer A, Liu E. Respiratory burst activity in MDS and MPS patients. *Br J Haematol.* 1994 Nov;88(3):663-4.
53. Cance WG, Craven RJ, Bergman M, Xu LH, Alitalo K, **Liu ET**. Rak, a novel tyrosine kinase expressed in epithelial cells. *Cell Growth & Differentiation* 3:1347-1355, 1994.
54. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, **Liu ET**, Cance WG. Receptor Tyrosine Kinases Processed and Overexpressed in the Progression of Colon Cancer. *Int. J. Cancer*, 60:791-797, 1995
55. O'Bryan JP, Fridell YW, Varnum B, Koski R, **Liu ET**. The receptor tyrosine kinase, axl, is processed by proteolytic cleavage of the ligand binding domain. *J. Biol Chem*, 270(2):551-557, 1995.
56. Augustine KA, **Liu ET**, Sadler TW. Interactions of Wnt-1 and Wnt-3a Are Essential for Neural Tube Patterning. *Teratology* 51:107-119, 1995.
57. Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, **Liu ET**. The Carolina Breast Cancer Study: Integrating population base epidemiology and molecular biology. *Breast Cancer and Treatment*, 35:51-60, 1995.
58. **Liu ET**. The Specialized Program of Research Excellence in Breast Cancer at the University of North Carolina at Chapel Hill. *Breast Cancer Research and Treatment*, 35:1-5, 1995.
59. Sorensen M, **Liu ET**. With a different voice: Integrating the psychosocial perspective into routine oncology care. *Breast Cancer Research and Treatment*, 35:39-42, 1995.
60. Conway K, Edmiston S, Fried DB, Hulka BS, Garret PA, **Liu ET**. Ha-ras rare alleles in breast cancer susceptibility. *Breast Cancer Research and Treatment*, 35:97-104, 1995.
61. Cance WG, **Liu ET**. Protein kinases in human breast cancer. *Breast Cancer Research and Treatment*, 35:105-114, 1995.
62. Owens LV, Craven RJ, Dent GA, Weiner TM, Kornberg L, **Liu ET**, Cance WG. Overexpression of the focal adhesion kinase in invasive human tumors. *Cancer Res.* 55, 2752-2755, 1995.
63. Varnum BC, Young C, Elliot G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, Toso RJ, Yanagihara D, Bennett L, Silber M, Merewether LA, Tseng A, Escobar E, **Liu ET**, Yamane HK. Growth Arrest Specific Gene 6 Protein is a Ligand for AXL, an Oncogenic Receptor Tyrosine Kinase. *Nature* 373:623-626, 1995.
64. Kute TE, Quadri Y, Hyman M, Zbieranski N, Cirrincione C, Berry D, Barcos M, Thor A, **Liu E**, Koerner F, Henderson IC. Flow Cytometry in Node Positive Breast Cancer: Cancer And Leukemia Group B Protocol 8869. *Cytometry* 22(4):297-306, 1995

65. Aprelikova O, Xiong Y, **Liu ET**. Both Families of CDK inhibitors block CDK phosphorylation by the CDK Activating Kinase (CAK.CDK7), *J. Bio Chem.*, 270:18195-18197, 1995.
66. Millikan, R., Hulka, B., Thor, A. Zhang, Y.C., Edgerton, S., Zhang, X.X., Pei, H., He, M., Wold, L., Melton, L.J., Ballard, D., Conway, K., and **Liu, E.T.** p53 mutations in Benign Breast Tissue. *J. Clin. Oncology*, 13(9):2293-2300, 1995.
67. Lai KS, Jin Y, Graham DK, Witthuhn BA, Ihle JN, **Liu ET**. A Kinase Deficient Splice Variant of the Human JAK3 is Expressed in Hematopoietic and Epithelial Cancer Cells. *J. Biol Chem.*, 270:1-9, 1995.
68. Craven, R.J., Cance, W.G., and **Liu, E.T.** The nuclear tyrosine kinase, Rak associates with the retinoblastoma protein pRb. *Cancer Research*, 55:3969-3972, 1995.
69. 68. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, Spizz G, Varnum B, Der C, **Liu ET**. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. *Mol Cell Biol*, 16(1):135-145, 1996.
70. Zariwala, M., **Liu, E**, and Xiong, Y. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors. *Oncogene*, 12:451-455, 1996.
71. Taylor JA, Li Y, He M, Mason T, Mettlin C, Vogler WJ, Maygarden S, **Liu E**. p53 mutations in bladder tumors from arylamine-exposed workers. *Cancer Research* 55:294-298, 1996.
72. Conway K, Edmiston SN, **Liu, ET**. Internal sequence variation in the Ha-Ras VNTR rare and common alleles identified by minisatellite variant repeat polymerase chain reaction. *Cancer Research*, 56(20):4773-4777, 1996.
73. Chen H, Sandler DP, Taylor JA, Shore DL, **Liu E**, Bloomfield CD, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1(GSTT1) gene defect. *Lancet* 347(8997):295-297, 1996
74. Aprelikova, O., Marjsten S, Kuthiala, A., Craven, R., Ethier, S., **Liu, E.T.**, Regulation of BRCA1 proteins by peptide growth factors. *Oncogene* 13(11):2487-2491, 1996.
75. Yarbrough WG, Aprelikova O, Pei H, Olshan AF, **Liu ET**. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. *J Natl Cancer Inst* 88(20):1489-1491, 1996.
76. Xu LH, Owens LV, Sturge GC, Yang X, **Liu ET**, Craven RJ, Cance WG. Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. *Cell Growth Differ* 7(4):413-418, 1996.
77. McCloskey P., Fridell Y.W., Attar E., Villa J., Varnum B., **Liu, E.T.** Gas6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl. *J. Biol. Chem.* 272(37): 23285-23291, 1997.
78. Loeser RF, Varnum BC, Carlson CS, Goldring MB, **Liu E.**, Sadiev S, Kute TE, Wallin R. Human Chondrocyte Expression of Growth-arrest-specific gene 6 and the Tyrosine Kinase Receptor Axl: Potential Role in Autocrine Signaling in Cartilage. *Arthritis & Rheumatism* 40:1455-1465, 1997.
79. Neubauer A, Burchert A, Maiwald C, Gruss H-J, Serke S, Huhn D, Wittig B, **Liu E**. Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. *Leukemia and Lymphoma* 25:91-96, 1997.
80. Fridell YWC, Villa J Jr, Attar EC, **Liu ET**. GAS6 induces axl-mediated chemotaxis of vascular smooth muscle cells. *J Biol Chem* 273(12):7123-7126, 1998.

81. Li Y, Millikan RC, Carozza S, Newman B, **Liu E**, Davis R, Miike R, Wensch M. p53 mutations in malignant gliomas. *Cancer Epidemiol., Biomarkers & Prevention.* 7:303-308, 1998.
82. Burchert A, Attar EC, McCloskey P, Fridell YWC, and Liu ET. Determinants for transformation induced by the AXL receptor tyrosine kinase. *Oncogene* Jun 18;16(24):3177-3187, 1998.
83. Guo Q, Xie J, Dang CV, **Liu ET**, and Bishop JM. Identification of a large Myc-binding protein that contains RCC1-like repeats. *Proc. Natl. Acad. Sci* 95: 9172-9177, 1998.
84. Honig GR, Suarez CR, Vida LN, Li, S-J, **Liu, ET**. Juvenile myelomonocytic leukemia (JMML) with the hematologic phenotype of severe α -thalassemia. *Am. J. Hematol.* 58: 67-71, 1998
85. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson, IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, and **Liu ET**. erbB-2, p53 and efficacy of adjuvant therapy in lymph node- positive breast cancer. *J Natl Cancer Inst* 90: 1346-1360, 1998.
86. Aprelikova O, Meissner E, Cotter S, Kuthiala A, Bessho M, and **Liu ET**. BRCA1 associated growth arrest is Rb dependent. *Proc Natl Acad Sci USA.* 96(21):11866-71, 1999.
87. Yarbrough WG, Buckmire R, Bessho M, **Liu ET**. Biological and biochemical analysis of p16INK4a mutations from primary tumors. *J Natl Cancer Inst.* 91(18):1569-74, 1999.
88. Li Y, Millikan RC, Newman B, Conway K, Tse CK, **Liu ET**. P57 (KIP2) polymorphisms and breast cancer risk. *Hum Genet* 104(1):83-88, 1999.
89. Pai L, Villa J, **Liu ET**, Pastan I. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. *Clin Cancer Res* 5(9):2311-5, 1999.
90. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ 3rd, **Liu ET**, Conway K. HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer. *J Clin Oncol* 18(2):267, 2000
91. Lee WP, Liao Y, Robinson D, Kung HJ, **Liu ET**, Hung MC. Axl-Gas6 Interaction Counteracts E1A-Mediated Cell Growth Suppression and Proapoptotic Activity. *Mol Cell Biol* 19(12):8075-8082, 1999.
92. Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, **Liu ET**. Risk of breast cancer according to the status of HER2/neu oncogene amplification. *Cancer Epidemiol Biomarkers Prev* 9(1):65-71, 2000.
93. Guo QB, Malek R, Kim S, Chiao C, He M, Ruffy M, Sanka K, Lee NH, Dang CV, **Liu ET**. Identification of c-Myc Target Genes Using Rat cDNA Microarray, *Cancer Res.* 60(21):5922-8, 2001.
94. Wang E, Miller LD, Ohnmacht GA, **Liu ET** and Marincola FM. High fidelity mRNA amplification for gene profiling. *Nat Biotechnol* 18(4):457-459, 2000.
95. Berry DA, Muss HB, Thor AD, Dressler LG, **Liu ET**, Broadwater GJ, Budman DR, Henderson CI, Barcos MP, Hayes DF, Norton L. HER-2/neu and p53 expression vs. tamoxifen resistance in estrogen-receptor-positive node-positive breast cancer. *J Clin Oncol.* 18(20):3471-9, 2000.
96. Campbell M, Aprelikova, ON, van der Meer R, Woltjer RL, Yee, CJ, **Liu ET**, Jensen RA. Construction and Characterization of recombinant adenoviruses expressing human BRCA1 or murine Brcal genes. *Cancer Gene Ther.* 8(3):231-9, 2001.
97. Miller LD, Park KS, Guo QB, Alkharouf NW, Malek RL, Lee NH, **Liu ET**, and Cheng SY. Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation. *Mol Cell Biol.* 21(19):6626-39, 2001.

98. Aprelikova ON, Pace A, Fang A, Koller B, and **Liu ET**. BRCA1 gene is required for 14-3-3 sigma gene expression. *J Biol Chem*. 276(28):25647-50, 2001.
99. Lee T, Miller L.D., Gubin A.N., Makhlof F., Wojda U., Barrett A.J., **Liu E.T.**, Miller J.L.. Transcriptional Patterning of Myelodysplastic Bone Marrow Using Erythroid Focused cDNA Arrays. *Blood*. 98(6):1914-21, 2001.
100. Zhou Y, Gawdry FG, Reinhold WC, Miller L, Smith LH, Scherf U, Kohn KW, **Liu ET**, Pommier Y, Weinstein JN. Transcriptional regulation of mitotic genes by camptothecin induced DNA damage: microarray analysis of dose and time-dependent effects. *Cancer Res* 62(6):1688-95, 2002.
101. Dong G, Loukinova E, Chen Z, Gangi L, **Liu ET**, and Van Waes C. Molecular Profiling of Metastatic Tumor Progression of a Murine Squamous Cell Carcinoma by Differential Display and cDNA Microarray Reveals Dysregulated Expression of Genes Related to the Nuclear Factor-kB Signal Pathway. *Cancer Res*. 61(12):4797-808, 2001.
102. Laura Assersohn, L Gangi, Y Zhao, M Dowsett, R Simon, T Powles, **ET. Liu**. The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. *Clin Cancer Res*; 8(3):794-801, 2002
103. Conway K, Edmiston S, Cui L, Drouin S, Pang JZ, Tse CK, Geradts J, Dressler L, **Liu ET**, Millikan R, Newman B. The Prevalence and Spectrum of p53 Implicates Smoking in Breast Cancer Development. *Cancer Res*. 62(7):1987-95, 2002.
104. Green JE, Cardiff, R, Henninghausen L, Wakefield L, Wagner U, Lee E, Rosen J, Medina D, Nitkin A, **Liu E**. Validation of Transgenic Mammary Cancer Models: Goals of the NCI Mouse Models of Human Cancer Consortium. *Transgenic Research* 11(6):635-636 (2002)
105. Sotiriou C, Khanna C, Petersen D, Jazaeri AA, and **Liu ET**. Core Biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. *J. Mol Diagnostics*;4(1):30-6, 2002
106. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Petersen D, Zhao YD, Simon R, Powell JI, Asaki E, Alexander HR, Duray P, Herlyn M, Restifo NP, **Liu ET**, Rosenberg SA, Marincola FM. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. *Cancer Res* 62(13):3581-6, 2002.
107. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, and **Liu ET**. FNA-derived gene expression profiles correlate with response to systemic chemotherapy in breast cancer. *Breast Cancer Research*. 4(4):141-4, 2002
108. Jazaeri A, Boyd J, McShane L, **Liu ET**. Expression profiling of ovarian cancers in BRCA1 and BRCA2 carriers. *J Natl Cancer Inst*. 3;94(13):990-1000, 2002
109. Kartiki V. Desai, N. Xiao, W. Wang, L. Gangi, J. Greene, J.I. Powell, R. Dickson, P. Furth, K. Hunter, J. Heyer, R. Kucherlapati, R. Simon, **ET Liu**, J.E. Green. Defining Gene Expression Signatures of Mammary Tumors Based Upon the Initiating Oncogenic Event: identification of novel oncogene-specific markers. *Proc Natl Acad Sci U S A*. 99(10):6967-72, 2002
110. Edgerton ME, Taylor R, Powell JI, Hunter L, Simon R, **Liu ET**. A bioinformatics tool to select sequences for microarray studies of mouse models of oncogenesis. *Bioinformatics* 18(5):774-775, 2002
111. Cozma D, Lukes L, Rouse J, Qiu TH, **Liu ET**, Hunter KW. A Bioinformatics-Based Strategy Identifies c-Myc and Cdc25A as Candidates for the Apmt Mammary Tumor Latency Modifiers. *Genome Res*. 12(6):969-75, 2002.

112. Bishop PC, Myers T, Robey R, Fry DW, **Liu ET**, Blagosklonny MV, Bates SE. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. *Oncogene*. 21(1):119-27, 2002
113. Yu Q, He M, Lee NH, **Liu ET**. Identification of Myc-mediated death response pathways by microarray analysis. *J Biol Chem* 277(15):13059-66, 2002.
114. Chandrasekharan S, Qiu TH, Alkharouf N, Brantley K, Mitchell JB, **Liu ET**. Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak. *Mol Cell Biol*. 22(14):5235-47, 2002.
115. Malek RL, Irby RB, Guo QM, Lee K, Wong S, He M, Tsai J. Frank B, **Liu ET**, Quackenbush J, Jove R, Yeatman TJ, Lee NH. Identification of Src transformation fingerprint in human colon cancer. *Oncogene* 21(47):7256-65 (2002).
116. Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, Figg WD, Alexander HR, **Liu ET**, Kohn EC, Libutti SK. Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay. *Biotechniques*. 33(3):664-6, 668, 670. (2002)
117. Shan L, He M, Yu M, Qiu C, Lee NH, **Liu ET**, Snyderwine EG. cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. *Carcinogenesis* 23(10):1561-8 (2002)
118. Chuang YYE, Chen Y , Chandramouli GVR , Cook JA , Coffin D, Tsai MH , DeGraff W , Yan HL , Zhao SP , Russo A, **Liu ET**, and Mitchell JB. Gene Expression Following Treatment with Hydrogen Peroxide, Menadione, or t-Butyl Hydroperoxide in Breast Cancer Cells. *Cancer Res*. 62(21):6246-54. (2002)
119. Pusztai Lajos, Sotiriou Christos, Buchholz Thomas A., Meric Funda, Symmans W. Fraser, Esteva Francisco J., Sahin Aysegul, **Liu E.T.**, Hortobagyi Gabriel N.. Molecular profiles of invasive mucinous and invasive ductal carcinomas of the breast, a molecular case study. *Cancer Genet Cytogenet*. 141(2):148-53, 2003.
120. Meyer T, Xu L, Chang J, **Liu ET**, Craven RJ, Cance WG. Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase. *Int J Cancer*. 104(2):139-46. 2003
121. A.A. Jazaeri, K. Lu, R. Schmandt, CP. Harris, PH. Rao, C. Sotiriou, G. V. R. Chandramouli, DM. Gershenson, **ET. Liu**. Molecular Determinants of Tumor Differentiation in Papillary Serous Ovarian Carcinoma. *Mol Carcinog*. 36(2):53-9. 2003
122. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, **Liu E**, Kirsch IR, Urasaki Y, Pommier Y, Weinstein JN. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. *Cancer Res*. 63(5):1000-11, 2003.
123. Vladimir B. Bajic, Sin Lam Tan, Allen Chong, Suisheng Tang, Anders Ström, Jan-Åke Gustafsson, Chin-Yo Lin, **E.T. Liu**. Dragon ERE FINDER ver.2: A tool for accurate detection of estrogen response response elements in vertebrate genomes. *Nucleic Acids Res*. 31(13):3605-7, 2003.
124. Lorenz MG, Cortes LM, Lorenz JJ, **Liu ET**. Strategy for the design of custom cDNA microarrays. *Biotechniques*. 34(6):1264-70, 2003.

125. Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau H, Su ST, Chia JM, Ng P, Chiu KP, Lim L, Zhang T, Peng CK, Lin EO, Lee NM, Yee SL, Ng LF, Chee RE, Stanton LW, Long PM, **Liu ET**. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. *Lancet*. 361(9371):1779-85, 2003.
126. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, **Liu ET**. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. *Proc Natl Acad Sci U S A*. 100(18):10393-8, 2003.
127. Hunter K, Welch DR, **Liu ET**. Genetic background is an important determinant of metastatic potential. *Nat Genet*. 34(1):23-4 (2003)
128. Lisa F. P. Ng, Michelle Wong, Susie Koh, Ooi Eng Eong, Tang Kin Fai, Leong HoeNam, Ling Ai Ee, Lora V. Agathe, Jenny Tan, **Liu ET**, Ren Ee Chee, Ng LeeChing and Martin L. Hibberd. Detection of SARS CoV in blood of infected patients. *J Clin Microbiol*. 42(1):347-50 (2004)
129. Philip M. Long, K.R. Krishna Murthy, Vinsensius Berlian Vega and **Edison T. Liu**, "Weighing Evidence in the Absence of a Gold Standard with Application to Genome-by-Genome Ortholog Mapping", *Eighth Annual International Conference on Research in Computational Molecular Biology (RECOMB 2004)*.
130. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, **Liu ET**, Yu Q. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. *J Biol Chem*. 279(20):21183-92. (2004)
131. Neo SY, Leow CK, Vega VB, Long PM, Islam AF, Lai PB, **Liu ET**, Ren EC. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. *Hepatology*. 39(4):944-53. (2004)
132. Wong CW, Albert TJ, Vega VB, Norton JE, Cutler DJ, Richmond TA, Stanton LW, **Liu ET**, Miller LD. Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. *Genome Res*. 2004 Mar;14(3):398-405.
133. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, **Liu ET**, Giavazzi R. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. *Mol Cancer Ther*. 2004 Feb;3(2):111-21.
134. Miller LD, McPhie P, Suzuki H, Kato Y, **Liu ET**, Cheng SY. Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance. *Genome Biol*. 5(5):R31. Epub (2004).
135. Wei CL, Ng P, Chiu KP, Wong CH, Ang CC, Lipovich L, **Liu ET**, Ruan Y. 5' Long serial analysis of gene expression (LongSAGE) and 3' LongSAGE for transcriptome characterization and genome annotation. *Proc Natl Acad Sci U S A*. 101(32):11701-6. (2004) Epub 2004 Jul 22.
136. Gilmore PM, McCabe N, Quinn JE, Kennedy RD, Gorski JJ, Andrews HN, McWilliams S, Carty M, Mullan PB, Duprex WP, **Liu ET**, Johnston PG, Harkin DP. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. *Cancer Res* 64(12):4148-54. (2004)
137. Welsh M, Welsh C, Ekman M, Dixelius J, Hagerkvist R, Anneren C, Akerblom B, Mahboobi S, Chandrasekharan S, **Liu ET**. The FRK/RAK tyrosine kinase participates in cytokine-induced islet cell toxicity. *Biochem J*. 382(Pt 1):261-8 (2004).

138. Chia KS, Lee JJ, Cheung P, Cheung KH, Seielstad M, Wilcox MM, **Liu E**. Twin births in Singapore: a population-based study using the National Birth Registry. *Ann Acad Med Singapore*. 33(2):195-9 (2004).
139. Wykoff CC, Sotiriou C, Cockman ME, Ratcliffe PJ, Maxwell P, **Liu E**, Harris AL. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. *Br J Cancer*. 90(6):1235-43. (2004)
140. Wang Z, Li Y, **Liu ET**, Yu Q. Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. *Biochem Biophys Res Commun*. 322(2):609-13. (2004)
141. Ng LF, Hibberd ML, Ooi EE, Tang KF, Neo SY, Tan J, Murthy KR, Vega VB, Chia JM, **Liu ET**, Ren EC. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. *BMC Infect Dis*. 9;4(1):34 (2004)
142. Vega VB, Ruan Y, Liu J, Lee WH, Wei CL, Se-Thoe SY, Tang KF, Zhang T, Kolatkar PR, Ooi EE, Ling AE, Stanton LW, Long PM, **Liu ET**. Mutational dynamics of the SARS coronavirus in cell culture and human populations isolated in 2003. *BMC Infect Dis*. 4(1):32 (2004)
143. Lin CY, Strom A, Vega VB, Li Kong S, Li Yeo A, Thomsen JS, Chan WC, Doray B, Bangarusamy DK, Ramasamy A, Vergara LA, Tang S, Chong A, Bajic VB, Miller LD, Gustafsson JA, **Liu ET**. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. *Genome Biol*. 5(9):R66. Epub 2004 Aug 12. (2004)
144. Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, **Liu ET**. Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT transgenic mice: correlation to human disease. *Cancer Res*. 64(17):5973-81. (2004)
145. Jazaeri AA, Chandramouli GV, Aprelikova O, Nuber UA, Sotiriou C, **Liu ET**, Ropers HH, Yee CJ, Boyd J, Barrett JC. BRCA1-mediated repression of select X chromosome genes. *J Transl Med*. 21;2(1):32. (2004)
146. Lung HL, Cheng Y, Kumaran MK, **Liu ET**, Murakami Y, Chan CY, Yau WL, Ko JM, Stanbridge EJ, Lung ML. Fine mapping of the 11q22-23 tumor suppressive region and involvement of TSLC1 in nasopharyngeal carcinoma. *Int J Cancer*. 20;112(4):628. (2004)
147. Ng LF, Hibberd ML, Ooi EE, Tang KF, Neo SY, Tan J, Murthy KR, Vega VB, Chia JM, **Liu ET**, Ren EC. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. *BMC Infect Dis*. 2004 Sep 9 [Epub ahead of print] PMID: 15357874
148. Lebowitz PF, Eng-Wong J, Swain SM, Berman A, Merino MJ, Chow CK, Venzon D, Zia F, Danforth D, **Liu E**, Zujewski J. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. *Clin Cancer Res*. 10(20):6764-9. (2004)
149. Peng X, Murthy Karuturi RK, Miller LD, Lin K, Jia Y, Kondu P, Wang L, Wong LS, Liu **ET**, Balasubramanian MK, Liu J. Identification of Cell Cycle-regulated Genes in Fission Yeast. *Mol Biol Cell*. 16(3):1026-42 (2005)
150. Steffensen KR, Neo SY, Stulnig TM, Vega VB, Rahman SS, Schuster GU, Gustafsson JA, **Liu ET**. Genome-wide expression profiling; a panel of mouse tissues discloses novel biological functions of liver X receptors in adrenals. *J Mol Endocrinol*. 33(3):609-22. (2004)

151. Lung HL, Cheng Y, Kumaran MK, **Liu ET**, Murakami Y, Chan CY, Yau WL, Ko JM, Stanbridge EJ, Lung ML. Fine mapping of the 11q22-23 tumor suppressive region and involvement of TSLC1 in nasopharyngeal carcinoma. *Int J Cancer*. 112(4):628-35. (2004)
152. Wei CL, Miura T, Robson P, Lim SK, Xu XQ, Lee MY, Gupta S, Stanton L, Luo Y, Schmitt J, Thies S, Wang W, Khrebtukova I, Zhou D, **Liu ET**, Ruan YJ, Rao M, Lim B. Transcriptome Profiling of Human and Murine ESCs Identifies Divergent Paths Required to Maintain the Stem Cell State. *Stem Cells*. 23(2):166-85 (2005).
153. Ng P, Wei CL, Sung WK, Chiu KP, Lipovich L, Ang CC, Gupta S, Shahab A, Ridwan A, Wong CH, **Liu ET**, & Ruan YJ. Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation *Nature Methods* **2**, 105 - 111 (2005)
154. Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, Kim H, Hyung WJ, Noh SH, Kim JH, Yun CO, **Liu ET**, Kim H. Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. *Oncogene*. 24(6):1066-1074. (2005)
155. Liu J, Lim SL, Ruan Y, Ling AE, Ng LF, Drosten C, **Liu ET**, Stanton LW, Hibberd ML. SARS Transmission Pattern in Singapore Reassessed by Viral Sequence Variation Analysis. *PLoS Med*. 2(2):e43. (2005)
156. Xu XQ, Emerald BS, Goh EL, Kannan N, Miller LD, Gluckman PD, **Liu ET**, Lobie PE. Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone (hGH) in human mammary carcinoma. *J Biol Chem*. 280(25):23987-4003 (2005)
157. Bimbo A, Jia Y, Poh SL, Karuturi RK, den Elzen N, Peng X, Zheng L, O'connell M, **Liu ET**, Balasubramanian MK, Liu J. Systematic deletion analysis of fission yeast protein kinases. *Eukaryot Cell*. 4(4):799-813 (2005).
158. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, **Liu ET**, Gannon F. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. *Oncogene*. 21;24(31):4894-907 (2005)
159. Lung HL, Bangarusamy DK, Xie D, Cheung AK, Cheng Y, Kumaran MK, Miller L, **Liu ET**, Guan XY, Sham JS, Fang Y, Li L, Wang N, Protopopov AI, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. *Oncogene*. 29;24(43):6525-32 (2005)
160. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, **Liu ET**, Thor A, Budman D, Muss H, Norton L, Hayes DF. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. *J Clin Oncol*. 2005 Jul 1;23(19):4287-97.
161. Smeds J, Miller LD, Bjohle J, Hall P, Klaar S, **Liu ET**, Pawitan Y, Ploner A, Bergh J. Gene profile and response to treatment. *Ann Oncol*. 2005;16 Suppl 2:ii195-202
162. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, **Liu ET*** and Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects and patient survival. *Proc Natl Acad Sci U S A*. 102(38):13550-5. (2005) *corresponding author

163. Mathavan S, Miller L.D., Korzh V., Gong Z., **Liu ET**, Lufkin T. Global analysis of gene expression during zebrafish embryogenesis using oligonucleotide microarray. *PLoS Genetics* 1(2):260-76 (2005)
164. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ, Wilming LG, Aidinis V, Allen JE, Ambesi-Impiombato A, Apweiler R, Aturaliya RN, Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T, Bono H, Chalk AM, Chiu KP, Choudhary V, Christoffels A, Clutterbuck DR, Crowe ML, Dalla E, Dalrymple BP, de Bono B, Della Gatta G, di Bernardo D, Down T, Engstrom P, Fagiolini M, Faulkner G, Fletcher CF, Fukushima T, Furuno M, Futaki S, Gariboldi M, Georgii-Hemming P, Gingeras TR, Gojobori T, Green RE, Gustincich S, Harbers M, Hayashi Y, Hensch TK, Hirokawa N, Hill D, Huminiecki L, Iacono M, Ieko K, Iwama A, Ishikawa T, Jakt M, Kanapin A, Katoh M, Kawasaki Y, Kelso J, Kitamura H, Kitano H, Kollias G, Krishnan SP, Kruger A, Kummerfeld SK, Kurochkin IV, Lareau LF, Lazarevic D, Lipovich L, Liu J, Liuni S, McWilliam S, Madan Babu M, Madera M, Marchionni L, Matsuda H, Matsuzawa S, Miki H, Mignone F, Miyake S, Morris K, Mottagui-Tabar S, Mulder N, Nakano N, Nakauchi H, Ng P, Nilsson R, Nishiguchi S, Nishikawa S, Nori F, Ohara O, Okazaki Y, Orlando V, Pang KC, Pavan WJ, Pavesi G, Pesole G, Petrovsky N, Piazza S, Reed J, Reid JF, Ring BZ, Ringwald M, Rost B, Ruan Y, Salzberg SL, Sandelin A, Schneider C, Schonbach C, Sekiguchi K, Semple CA, Seno S, Sessa L, Sheng Y, Shibata Y, Shimada H, Shimada K, Silva D, Sinclair B, Sperling S, Stupka E, Sugiura K, Sultana R, Takenaka Y, Taki K, Tammoja K, Tan SL, Tang S, Taylor MS, Tegner J, Teichmann SA, Ueda HR, van Nimwegen E, Verardo R, Wei CL, Yagi K, Yamanishi H, Zabarovsky E, Zhu S, Zimmer A, Hide W, Bult C, Grimmond SM, Teasdale RD, **Liu ET**, Brusic V, Quackenbush J, Wahlestedt C, Mattick JS, Hume DA, Kai C, Sasaki D, Tomaru Y, Fukuda S, Kanamori-Katayama M, Suzuki M, Aoki J, Arakawa T, Iida J, Imamura K, Itoh M, Kato T, Kawaji H, Kawagashira N, Kawashima T, Kojima M, Kondo S, Konno H, Nakano K, Ninomiya N, Nishio T, Okada M, Plessy C, Shibata K, Shiraki T, Suzuki S, Tagami M, Waki K, Watahiki A, Okamura-Oho Y, Suzuki H, Kawai J, Hayashizaki Y; FANTOM Consortium; RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group). The transcriptional landscape of the mammalian genome. *Science*. 2005 Sep 2;309(5740):1559-63.
165. Lipovich L, Vanisri RR, Kong SL, Lin CY, **Liu ET**. Primate-Specific Endogenous Cis-Antisense Transcription in the Human 5q31 Protocadherin Gene Cluster. *J Mol Evol*. 2005 Dec 6; [Epub ahead of print]
166. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, **Liu ET**, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. *Breast Cancer Res*. 2005 Oct 3;7(6):R953-R964
167. Zhang T, Breitbart M, Lee WH, Wei CL, Soh SWL, Hibberd ML, **Liu ET**, Ruan YJ. Prevalence of plant viruses in the RNA viral community of human feces. *PLoS Biology*. 2005 Dec 20;4(1):e3 [Epub ahead of print]
168. Zhao Y, Tan J, Zhuang L, Jiang X, **Liu ET**, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. *Proc Natl Acad Sci U S A*. 2005 Nov 1;102(44):16090-5. Epub 2005 Oct 21.

169. Tan J, Zhuang L, Leong HS, Iyer NG, **Liu ET**, Yu Q. Pharmacologic modulation of glycogen synthase kinase-3 β promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. *Cancer Res.* 2005 Oct 1;65(19):9012-20.
170. Lam SH, Wu YL, Vega VB, Miller LD, Spitsbergen J, Tong Y, Zhan H, Govindarajan KR, Lee S, Mathavan S, Krishna Murthy KR, Buhler DR, **Liu ET**, Gong Z. Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. *Nat Biotechnol.* 2006 Jan;24(1):73-5.
171. Chia Lin Wei, Qiang Wu, Vinsensius Vega, Kuo Ping Chiu, Patrick Ng, Tao Zhang, Atif Shahab, Azmi Ridwan, YuTao Fu, Zhiping Weng, Yen Ling Lee, Jian Jun Liu, Vladimir A. Kuznetsov, Ken Sung, Bing Lim, **Edison T. Liu**, Qiang Yu, Huck Hui Ng, and Yijun Ruan. A Global Mapping of p53 Transcription Factor Binding Sites in the Human Genome. *Cell.* 2006 Jan 13;124(1):207-19.
172. Broet P, Kuznetsov VA, Bergh J, **Liu E**, Miller LD. Identifying gene expression changes in breast cancer that distinguish early and late relapse among uncured patients. *Bioinformatics.* 22(12):1477-85 (2006).
173. Hall P, Ploner A, Bjohle J, Huang F, Lin CY, **Liu ET**, Miller LD, Nordgren H, Pawitan Y, Shaw P, Skoog L, Smeds J, Wedren S, Ohd J, Bergh J. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. *BMC Med.* 4(1):16 (2006)
174. Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, Ponjavic J, Semple CA, Taylor MS, Engstrom PG, Frith MC, Forrest AR, Alkema WB, Tan SL, Plessy C, Kodzius R, Ravasi T, Kasukawa T, Fukuda S, Kanamori-Katayama M, Kitazume Y, Kawaji H, Kai C, Nakamura M, Konno H, Nakano K, Mottagui-Tabar S, Arner P, Chesi A, Gustincich S, Persichetti F, Suzuki H, Grimmond SM, Wells CA, Orlando V, Wahlestedt C, **Liu ET**, Harbers M, Kawai J, Bajic VB, Hume DA, Hayashizaki Y. Genome-wide analysis of mammalian promoter architecture and evolution. *Nat Genet.* 38(6):626-635 (2006).
175. Lam SH, Winata CL, Tong Y, Korzh S, Lim WS, Korzh V, Spitsbergen J, Mathavan S, Miller LD, **Liu ET**, Gong Z. Transcriptome Kinetics of Arsenic-induced Adaptive Response in Zebrafish Liver. *Physiol Genomics.* 2006 Aug 1; [Epub ahead of print]
176. Eng-Wong J, Reynolds JC, Venzon D, Liewehr D, Gantz S, Danforth D, **Liu ET**, Chow C, Zujewski J. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. *J Clin Endocrinol Metab.* 2006 Jul 25; [Epub ahead of print]
177. Frasor J, Chang EC, Komm B, Lin CY, Vega VB, **Liu ET**, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. *Cancer Res.* 2006 Jul 15;66(14):7334-40.
178. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, **Liu ET**, Miller L, Ploner A, Smeds J, Bergh J, Pawitan Y. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. *Breast Cancer Res.* 2006 Jul 17;8(4):R34 [Epub ahead of print]
179. Einarsdottir K, Humphreys K, Bonnard C, Palmgren J, Iles MM, Sjolander A, Li Y, Chia KS, **Liu ET**, Hall P, Liu J, Wedren S. Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk. *PLoS Med.* 2006 Jun;3(6):e168. Epub 2006 May 9.

180. Nilsson M, Stulnig TM, Lin CY, Yeo AL, Nowotny P, **Liu ET**, Steffensen KR. Liver X receptors regulate adrenal steroidogenesis and hypothalamic-pituitary-adrenal feedback. *Mol Endocrinol*. 2006 Sep 14; [Epub ahead of print]
181. Vega VB, Lin CY, Lai KS, Kong SL, Xie M, Su X, Teh HF, Thomsen JS, Yeo AL, Sung WK, Bourque G, **Liu ET**. Multi-platform genome-wide identification and modeling of functional human estrogen receptor binding sites. *Genome Biol*. 2006 Sep 9;7(9):R82 [Epub ahead of print]
182. Einarsdottir K, Humphreys K, Bonnard C, Li Y, Li Y, Chia KS, **Liu ET**, Hall P, Liu J, Wedren S. Effect of ATM, CHEK2 and ERBB2 tagSNPs and haplotypes on endometrial cancer risk. *Hum Mol Genet*. 2006 Dec 12; [Epub ahead of print]
183. Einarsdottir K, Rosenberg LU, Humphreys K, Bonnard C, Palmgren J, Li Y, Li Y, Chia KS, **Liu ET**, Hall P, Liu J, Wedren S. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. *Breast Cancer Res*. 2006 Nov 28;8(6):R67 [Epub ahead of print].
184. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, **Liu ET**, Bergh J, Kuznetsov VA, Miller LD. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. *Cancer Res*. 2006 Nov 1;66(21):10292-301.
185. Mohankumar KM, Xu XQ, Zhu T, Kannan N, Miller LD, **Liu ET**, Gluckman PD, Sukumar S, Emerald BS, Lobie PE. HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. *Oncogene*. 2007 Jan 8; [Epub ahead of print]
186. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, **Liu ET**, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. *Genes Dev*. 2007 May 1;21(9):1050-63.
187. Lin CY, Strom A, Kong SL, Kietz S, Thomsen JS, Tee JB, Vega VB, Miller LD, Smeds J, Bergh J, Gustafsson JA, **Liu ET**. Inhibitory effects of estrogen receptor beta on specific hormone responsive gene expression and association with disease outcome in primary breast cancer. *Breast Cancer Res*. 2007 Apr 11;9(2):R25
188. Chin-Yo Lin, Vinsensius B. Vega, Jane S. Thomsen, Tao Zhang, Say Li Kong, Min Xie, Kuo Ping Chiu, Leonard Lipovich, Daniel H. Barnett, Fabio Stossi, Ailing Yeo, Joshy George, Vladimir A. Kuznetsov, Yew Kok Lee, Tze Howe Charn, Nallasivam Palanisamy, Lance D. Miller, Edwin Cheung, Benita S. Katzenellenbogen, Yijun Ruan, Guillaume Bourque, Chia-Lin Wei, **Edison T. Liu**. Whole-genome Cartography of Estrogen Receptor α Binding Sites. *PLoS Genetics* 2007 Jun 1;3(6):e87
189. Eshaghi M, Karuturi RK, Li J, Chu Z, **Liu ET**, Liu J. Global profiling of DNA replication timing and efficiency reveals that efficient replication/firing occurs late during S-phase in *S. pombe*. *PLoS ONE*. 2007 Aug 8;2(1):e722.
190. Chiu KP, Ariyaratne P, Xu H, Tan A, Ng P, **Liu ET**, Ruan Y, Wei CL, Sung WK. Pathway aberrations of murine melanoma cells observed in Paired-End diTag transcriptomes. *BMC Cancer*. 2007 Jun 26;7:109.
191. Leung AC, Wong VC, Yang LC, Chan PL, Daigo Y, Nakamura Y, Qi RZ, Miller LD, **Liu ET**, Wang LD, Li JL, Law S, Tsao SW, Lung ML. Frequent decreased expression of candidate tumor

- suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. *Int J Cancer*. 2007 Oct 17; [Epub ahead of print]
192. Denger S, Bahr-Ivacevic T, Brand H, Reid G, Blake J, Seifert M, Lin CY, May K, Benes V, **Liu ET**, Gannon F. Transcriptome profiling of estrogen-regulated genes in human primary osteoblasts reveals an osteoblast specific regulation of the IGFBP4 gene. *Mol Endocrinol*. 2008 Feb;22(2):361-79.
 193. Einarsdóttir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, Sjölander A, Czene K, Wedrén S, **Liu ET**, Hall P, Humphreys K, Liu J. ESR1 and EGF genetic variation in relation to breast cancer risk and survival. *Breast Cancer Res*. 2008 Feb 14;10(1):R15 [Epub ahead of print]
 194. Digiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, **Liu ET**, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B. *J Clin Oncol*. 2008 May 10;26(14):2364-72.
 195. Ko JM, Chan PL, Yau WL, Chan HK, Chan KC, Yu ZY, Kwong FM, Miller LD, **Liu ET**, Yang LC, Lo PH, Stanbridge EJ, Tang JC, Srivastava G, Tsao SW, Law S, Lung ML. Monochromosome Transfer and Microarray Analysis Identify a Critical Tumor-Suppressive Region Mapping to Chromosome 13q14 and THSD1 in Esophageal Carcinoma. *Mol Cancer Res*. 2008 Apr;6(4):592-603.
 196. Barnett DH, Sheng S, Charn TH, Waheed A, Sly WS, Lin CY, **Liu ET**, Katzenellenbogen BS. Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. *Cancer Res*. 2008 May 1;68(9):3505-15.
 197. Lam SH, Mathavan S, Tong Y, Li H, Karuturi RK, Wu Y, Vega VB, **Liu ET**, Gong Z. Zebrafish whole-adult-organism chemogenomics for large-scale predictive and discovery chemical biology. *PLoS Genet*. 2008 Jul 11;4(7):e1000121.
 198. Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, **Liu ET**, Bloomfield CD. Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study. *J Clin Oncol*. 2008 Oct 1;26(28):4603-9.
 199. Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, **Liu ET**, Cheyette BN, Yu Q. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. *Cancer Cell*. 2008 Jun;13(6):529-41.
 200. Bourque G, Leong B, Vega VB, Chen X, Lee YL, Srinivasan KG, Chew JL, Ruan Y, Wei CL, Ng HH, **Liu ET**. Evolution of the mammalian transcription factor binding repertoire via transposable elements. *Genome Res*. 2008 Nov;18(11):1752-62.
 201. Pan YF, Wansa KD, Liu MH, Zhao B, Hong SZ, Tan PY, Lim KS, Borque G, **Liu ET**, Cheung E. Regulation of estrogen receptor-mediated long-range transcription via evolutionarily conserved distal response elements. *J Biol Chem*. 2008 Aug 25. [Epub ahead of print]
 202. Cheung AK, Lung HL, Hung SC, Law EW, Cheng Y, Yau WL, Bangarusamy DK, Miller LD, **Liu ET**, Shao JY, Kou CW, Chua D, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. *Cancer Res*. 2008 Oct 1;68(19):8137-45.

203. Hamza MS, Pott S, Vega VB, Thomsen JS, Kandhadayar GS, Ng PW, Chiu KP, Pettersson S, Wei CL, Ruan Y, **Liu ET**. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. *PLoS ONE*. 2009;4(3):e4907.
204. Einarsdóttir K, Darabi H, Czene K, Li Y, Low YL, Li YQ, Bonnard C, Wedrén S, **Liu ET**, Hall P, Liu J, Humphreys K. Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival. *Br J Cancer*. 2009 Apr 21;100(8):1358-64.
205. Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, Leong WY, Chan YS, Palanisamy N, **Liu ET**, Karuturi KM, Lim B, Miller LD. RCP is a human breast cancer-promoting gene with Ras-activating function. *J Clin Invest*. 2009 Aug;119(8):2171-83. doi: 10.1172/JCI37622. Epub 2009 Jul 20.
206. Melissa J. Fullwood, You Fu Pan, Han Xu, Vinsensius B. Vega, Phillips Yao Hui Huang, Mei Hui Liu, Yusoff Bin Mohamed, Pramila N. Ariyaratne, Peck Yean Tan, Pei Ye Choy, Roy Joseph, Kartiki V. Desai, Jane S. Thomsen, Yew Kok Lee, Haixia Li, R. Krishna Murthy Karuturi, Thoreau Herve, Guillaume Bourque, Valere Cacheux-Rataboul, Ken W. K. Sung, **Edison T. Liu**, Chia Lin Wei, Edwin Cheung, Yijun Ruan. The Estrogen Receptor α -mediated Human Chromatin Interactome. *Nature*, 2009 Nov 5;462(7269):58-64.
207. Jin L, **Liu ET**, Seielstad M, Xu SH (writing group):Mapping Human Genetic History in Asia.. The HUGO Pan-Asian SNP Consortium. *Science*, 326(5959):1541-5. (2009)
208. Charn TH, **Liu ET**, Chang EC, Lee YK, Katzenellenbogen JA, Katzenellenbogen BS. Genome-Wide Dynamics of Chromatin Binding of Estrogen Receptors α and β : Mutual Restriction and Competitive Site Selection. *Mol Endocrinol*. 2010; 24(1):47-59.
209. Jianjun Liu, Kartiki Vasant Desai, Yuqing Li, Shakeela Banu, Yew Kok Lee, Dianbo Qu, Tuomas Heikkinen, Kirsimari Aaltonen, Taru A. Muranen, Tasneem Shabbir Kajiji, Carine Bonnard, Kristiina Aittomäki, Karl von Smitten, Carl Blomqvist, John L. Hopper, Melissa C. Southey, Hiltrud Brauch, The GENICA Consortium, Georgia Chenevix-Trench, Jonathan Beesley, Amanda B. Spurdle, Xiaoqing Chen, Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer, Australian Ovarian Cancer Study Group, Kamila Czene, Per Hall, Heli Nevanlinna, **Edison T. Liu**. Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development. *HUGO Journal* (2009) Dec;3(1-4):31-40. Epub 2010 Apr 13. 3:31–40
210. Gold-Nanoparticle-Based Assay for Instantaneous Detection of Nuclear Hormone Receptor-Response Elements Interactions. Tan YN, Su X, **Liu ET**, Thomsen JS. *Anal Chem*. 82(7):2759-65 (2010)
211. Kang J, Qian PX, Pandey V, Perry JK, Miller LD, **Liu ET**, Zhu T, Liu DX, Lobie PE. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. *Oncogene*. 2010 Mar 22. [Epub ahead of print].
212. Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, **Liu ET**, Mertani HC, Zhu T, Grandison PM, Liu DX, Lobie PE. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. 2010 Dec;12(12):1041-53.

213. Treiber T, Mandel EM, Pott S, Györy I, Firner S, **Liu ET**, Grosschedl R. Early B Cell Factor 1 Regulates B Cell Gene Networks by Activation, Repression, and Transcription- Independent Poising of Chromatin. *Immunity*. 2010 May 28;32(5):714-25..
214. Low YL, Li Y, Humphreys K, Thalamuthu A, Li Y, Darabi H, Wedrén S, Bonnard C, Czene K, Iles MM, Heikkinen T, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, **Liu ET**, Liu J. Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. *PLoS Genet*. 2010 Jul 1;6:e1001012.
215. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, Feng QS, Low HQ, Zhang H, He F, Tai ES, Kang T, **Liu ET**, Liu J, Zeng YX. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. *Nat Genet*. 2010 Jul;42(7):599-603. Epub 2010 May 30.
216. Gong M, Foo SH, Lin L, **Liu ET**, Gharizadeh B, Goel S. Pyrosequencing enhancement for better detection limit and sequencing homopolymers. *Biochem Biophys Res Commun*. 2010 Oct 8;401(1):117-23.
217. Zhang GJ, Huang MJ, Luo ZH, Tay GK, Lim EJ, **Liu ET**, Thomsen JS. Highly sensitive and reversible silicon nanowire biosensor to study nuclear hormone receptor protein and response element DNA interactions. *Biosens Bioelectron*. 2010 Oct 15;26(2):365-70.
218. Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, **Liu ET**, Mertani HC, Zhu T, Grandison PM, Liu DX, Lobie PE. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. *Neoplasia*. 2010 Dec;12(12):1041-53.
219. Joseph R, Orlov YL, Huss M, Sun W, Kong SL, Ukil L, Pan YF, Li GL, Lim M, Thomsen JS, Ruan YJ, Clarke ND, Prabhakar S, Cheung E, **Liu ET**. Integrative model of genomic factors for determining binding site selection by estrogen receptor α . *Mol Systems Biology*, 2010 Dec 21;6:456.
220. Li Y, Li Y, Wedren S, Li G, Charn TH, Vasant DK, Bonnard C, Czene K, Humphreys K, Darabi H, Einarsdttir K, Heikkinen T, Aittomaki K, Blomqvist C, Chia KS, Nevanlinna H, Hall P, **Liu ET**, Liu J. Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor positive breast cancer. *Breast Cancer Res*. 2011 Jan 26;13(1):R10. [Epub ahead of print].
221. Hillmer AM, Yao F, Inaki K, Lee WH, Ariyaratne PN, Teo AS, Woo XY, Zhang Z, Zhao H, Ukil L, Chen JP, Zhu F, So JB, Salto-Tellez M, Poh WT, Zawack KF, Nagarajan N, Gao S, Li G, Kumar V, Lim HP, Sia YY, Chan CS, Leong ST, Neo SC, Choi PS, Thoreau H, Tan PB, Shahab A, Ruan X, Bergh J, Hall P, Cacheux-Rataboul V, Wei CL, Yeoh KG, Sung WK, Bourque G, **Liu ET**, Ruan Y. Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. *Genome Res*. 2011 May;21(5):665-75.
222. Inaki K, Hillmer AM, Ukil L, Yao F, Woo XY, Vardy LA, Zawack KF, Lee CW, Ariyaratne PN, Chan YS, Desai KV, Bergh J, Hall P, Putti TC, Ong WL, Shahab A, Cacheux-Rataboul V,

- Karuturi RK, Sung WK, Ruan X, Bourque G, Ruan Y, **Liu ET**. Transcriptional consequences of genomic structural aberrations in breast cancer. *Genome Res* 2011 May;21(5):676-87.
223. Soon WW, Miller LD, Black MA, Dalmaso C, Chan XB, Pang B, Ong CW, Salto-Tellez M, Desai KV, **Liu ET**. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. *EMBO Mol Med*. 2011 Aug;3(8):451-64.
 224. Lam SH, Lee SG, Lin CY, Thomsen JS, Fu PY, Murthy KR, Li H, Govindarajan KR, Nick LCh, Bourque G, Gong Z, Lufkin T, **Liu ET**, Mathavan S. Molecular conservation of estrogen-response associated with cell cycle regulation, hormonal carcinogenesis and cancer in zebrafish and human cancer cell lines. *BMC Med Genomics*. 2011 May 16;4:41.
 225. Alfredsson L, Klareskog L, Glimelius B, Melbye M, **Liu ET**, Adami HO, Humphreys K, Liu J. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. *PLoS Genet*. 2011 Apr;7(4):e1001378. Epub 2011 Apr 21.
 226. Hatin WI, Nur-Shafawati AR, Zahri MK, Xu S, Jin L, Tan SG, Rizman-Idid M, Zilfalil BA; **HUGO Pan-Asian SNP Consortium**. Population genetic structure of peninsular Malaysia Malay sub-ethnic groups. *PLoS One*. 2011 Apr 5;6(4):e18312.
 227. Guo-Jun Zhang, Min Joon Huang, Jun'An Jason Ang, **Edison T. Liu**, Kartiki Vasant Desai Self-assembled monolayer-assisted silicon nanowire biosensor for detection of protein–DNA interactions in nuclear extracts from breast cancer cell. *Biosensors and Bioelectronics* 26: 3233–3239 (2011)
 228. Kong SL, Li GL, Loh SL, Sung WK, **Liu ET**. Cellular Reprogramming by the Conjoint Action of Estrogen receptor α , FOXA1, and GATA3 to a ligand inducible growth state. *Mol Syst Biol*. 2011 Aug 30;7:526.
 229. Yang X, Xu S; **HUGO Pan-Asian SNP Consortium**; Indian Genome Variation Consortium. Identification of close relatives in the HUGO Pan-Asian SNP database. *PLoS One*. 2011;6(12):e29502. Epub 2011 Dec 29.
 230. Ngamphiw C, Assawamakin A, Xu S, Shaw PJ, Yang JO, Ghang H, Bhak J, **Liu E**, Tongshima S; HUGO Pan-Asian SNP Consortium. PanSNPdb: the Pan-Asian SNP genotyping database. *PLoS One*. 2011;6(6):e21451. Epub 2011 Jun 23.
 231. Li G, Ruan X, Auerbach RK, Sandhu KS, Zheng M, Wang P, Poh HM, Goh Y, Lim J, Zhang J, Sim HS, Peh SQ, Mulawadi FH, Ong CT, Orlov YL, Hong S, Zhang Z, Landt S, Raha D, Euskirchen G, Wei CL, Ge W, Wang H, Davis C, Fisher-Aylor KI, Mortazavi A, Gerstein M, Gingeras T, Wold B, Sun Y, Fullwood MJ, Cheung E, **Liu E**, Sung WK, Snyder M, Ruan Y. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. *Cell*. 2012 Jan 20;148(1-2):84-98.

232. Györy I, Boller S, Nechanitzky R, Mandel E, Pott S, **Liu E**, Grosschedl R. Transcription factor Ebf1 regulates differentiation stage-specific signaling, proliferation, and survival of B cells. *Genes Dev.* 2012 Apr 1;26(7):668-82.
233. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, **Liu ET**, Desai KV. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. *Breast Cancer Res.* 2012 May 23;14(3):R85.
234. Xu S, Pugach I, Stoneking M, Kayser M, Jin L; HUGO Pan-Asian SNP Consortium. Genetic dating indicates that the Asian-Papuan admixture through Eastern Indonesia corresponds to the Austronesian expansion. *Proc Natl Acad Sci U S A.* 2012 Mar 20;109(12):4574-9. Epub 2012 Mar 6.
235. Yang X, Xu S; HUGO Pan-Asian SNP Consortium; Indian Genome Variation Consortium. Identification of close relatives in the HUGO Pan-Asian SNP database. *PLoS One.* 2011;6(12):e29502. Epub 2011 Dec 29.
236. Pott S, Kamrani NK, Bourque G, Pettersson S, **Liu ET**. PPARG Binding Landscapes in Macrophages Suggest a Genome-Wide Contribution of PU.1 to Divergent PPARG Binding in Human and Mouse. *PLoS One.* 2012;7(10):e48102. doi: 10.1371/journal.pone.0048102. Epub 2012 Oct 31.
237. Yao F, Ariyaratne PN, Hillmer AM, Lee WH, Li G, Teo AS, Woo XY, Zhang Z, Chen JP, Poh WT, Zawack KF, Chan CS, Leong ST, Neo SC, Choi PS, Gao S, Nagarajan N, Thoreau H, Shahab A, Ruan X, Cacheux-Rataboul V, Wei CL, Bourque G, Sung WK, **Liu ET**, Ruan Y. Long Span DNA Paired-End-Tag (DNA-PET) Sequencing Strategy for the Interrogation of Genomic Structural Mutations and Fusion-Point-Guided Reconstruction of Amplicons. *PLoS One.* 2012;7(9):e46152. Epub 2012 Sep 28.
238. Shinojima T, Yu Q, Huang SK, Li M, Mizuno R, Liu ET, Hoon DS, Lessard L. Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. *Epigenetics.* 2012 Nov 1;7(11):1279-89. doi: 10.4161/epi.22333. Epub 2012 Sep 28.
239. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, Wong M, Zhang Z, Li G, Sung WK, Zhou J, Chng WJ, Li S, **Liu E**, Tergaonkar V. Telomerase directly regulates NF- κ B-dependent transcription. *Nat Cell Biol.* 2012 Dec;14(12):1270-81. Epub 2012 Nov 18.
240. Ngamphiw C, Assawamakin A, Xu S, Shaw PJ, Yang JO, Ghang H, Bhak J, Liu E, Tongsima S; HUGO Pan-Asian SNP Consortium. PanSNPdb: the Pan-Asian SNP genotyping database. *PLoS One.* 2011;6(6):e21451. Epub 2011 Jun 23.
241. Sandhu KS, Li G, Poh HM, Quek YL, Sia YY, Peh SQ, Mulawadi FH, Lim J, Sikic M, Menghi F, Thalamuthu A, Sung WK, Ruan X, Fullwood MJ, **Liu E**, Csermely P, Ruan Y. Large-scale functional organization of long-range chromatin interaction networks. *Cell Rep.* 2012 Nov 29;2(5):1207-19. Epub 2012 Oct 25.

242. Tropberger P, Pott S, Keller C, Kamieniarz-Gdula K, Caron M, Richter F, Li G, Mittler G, **Liu ET**, Bühler M, Margueron R, Schneider R. Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. *Cell*. 2013 Feb 14;152(4):859-72.
243. Madak-Erdogan Z, Charn TH, Jiang Y, **Liu ET**, Katzenellenbogen JA, Katzenellenbogen BS. Integrative genomics of gene and metabolic regulation by estrogen receptors α and β , and their coregulators. *Mol Syst Biol*. 2013 Jun 18; 9:676.
244. Utami KH, Hillmer AM, Aksoy I, Chew EG, Teo AS, Zhang Z, Lee CW, Chen PJ, Seng CC, Ariyaratne PN, Rouam SL, Soo LS, Yousoof S, Prokudin I, Peters G, Collins F, Wilson M, Kakakios A, Haddad G, Menuet A, Perche O, Tay SK, Sung KW, Ruan X, Ruan Y, **Liu ET**, Briault S, Jamieson RV, Davila S, Cacheux V. Detection of chromosomal breakpoints in patients with developmental delay and speech disorders. *PLoS One*. 2014 Mar 6;9(6):e90852.
245. Inaki K, Menghi F, Woo XY, Wagner JP, Jacques PE, Lee YF, Shreckengast PT, Soon WW, Malhotra A, Teo AS, Hillmer AM, Khng AJ, Ruan X, Ong SH, Bertrand D, Nagarajan N, Karuturi RK, Hidalgo Miranda A, **Liu ET**. Systems consequences of amplicon formation in human breast cancer. *Genome Res*. 2014 Oct;24(10):1559-71.
246. Grzeda KR, Royer-Bertrand B, Inaki K, Kim H, Hillmer AM, **Liu ET**, Chuang JH. Functional chromatin features are associated with structural mutations in cancer. *BMC Genomics*. 2014 Nov 23;15:1013.
247. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, **Liu E**, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. *PLoS One*. 2015 Aug 13;10(8):e0134346.
248. Gandara DR, Mack PC, Bult C, Li T, Lara PN Jr, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, **Liu ET**. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. *Clin Lung Cancer*. 2015 May;16(3):165-72. doi: 10.1016/j.clcc.2015.03.001. Epub 2015 Mar 18.
249. Bertrand D, Chng KR, Sherbaf FG, Kiesel A, Chia BK, Sia YY, Huang SK, Hoon DS, **Liu ET**, Hillmer A, Nagarajan N. Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles. *Nucleic Acids Res*. 2015 Apr 20;43(7):e44.
250. Park H, Cho SY, Kim H, Na D, Han JY, Chae J, Park C, Park OK, Min S, Kang J, Choi B, Min J, Kwon JY, Suh YS, Kong SH, Lee HJ, **Liu ET**, Kim JI, Kim S, Yang HK, Lee C. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. *Proc Natl Acad Sci U S A*. 2015 Oct 6;112(40):12492-12497. Epub 2015 Sep 23.
251. Buisine N, Ruan X, Bilesimo P, Grimaldi A, Alfama G, Ariyaratne P, Mulawadi F, Chen J, Sung WK, **Liu ET**, Demeneix BA, Ruan Y, Sachs LM. *Xenopus tropicalis* Genome Re-Scaffolding and

Re-Annotation Reach the Resolution Required for In Vivo ChIA-PET Analysis. PLoS One. 2015 Sep 8;10(9):e0137526.

252. Tang Z, Luo OJ, Li X, Zheng M, Zhu JJ, Szalaj P, Trzaskoma P, Magalska A, Wlodarczyk J, Ruszczycki B, Michalski P, Piecuch E, Wang P, Wang D, Tian SZ, Penrad-Mobayed M, Sachs LM, Ruan X, Wei CL, **Liu ET**, Wilczynski GM, Plewczynski D, Li G, Ruan Y. CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription. *Cell*. 2015 Dec 17;163(7):1611-27.
253. Menghi F, Inaki K, Woo X, Kumar PA, Grzeda KR, Malhotra A, Yadav V, Kim H, Marquez EJ, Ucar D, Shreckengast PT, Wagner JP, MacIntyre G, Murthy Karuturi KR, Scully R, Keck J, Chuang JH, **Liu ET**. The tandem duplicator phenotype as a distinct genomic configuration in cancer. *Proc Natl Acad Sci U S A*. 2016 Apr 26;113(17):E2373-82
254. Arellano-Llamas R, Alfaro-Ruiz L, Arriaga Canon C, Imaz Rosshandler I, Cruz-Lagunas A, Zúñiga J, Rebollar Vega R, Wong CW, Maurer-Stroh S, Romero Córdoba S, **Liu ET**, Hidalgo-Miranda A, Vázquez-Pérez JA. Molecular features of influenza A (H1N1)pdm09 prevalent in Mexico during winter seasons 2012-2014. *PLoS One*. 2017 Jul 10;12(7):e0180419.
255. Willis NA, Frock RL, Menghi F, DuffeyEE, Panday A, Camacho V, Hasty EP, **Liu ET**, Alt FW, and Scully R. Mechanism of tandem duplication formation in BRCA1-mutant cells. *Nature* 2017 Nov 30;551(7682):590-595
256. Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, **Liu ET**, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG. Efficacy and Mechanisms of PD-1 Targeted Cancer Immunotherapy in Humanized Mice. *FASEB J* 2017 January 3; 32(3): 1537-1549.
257. Cho SY, Sung CO, Chae J, Lee J, Na D, Kang W, Kang J, Min S, Lee A, Kwak E, Kim J, Choi B, Kim H, Chuang JH, Pak HK, Park CS, Park S, Ko YH, Lee D, Roh J, Cho MS, Park S, Ju YS, Suh YS, Kong SH, Lee HJ, Keck J, Banchereau J, **Liu ET**, Kim WH, Park H, Yang HK, Kim JI, Lee C. Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments. *Blood*. 2018 Feb 23. (epub) pii: blood-2017-07-797209.
258. Gong L, Wong CH, Cheng WC, Tjong H, Menghi F, Ngan CY, **Liu ET**, Wei CL. Picky comprehensively detects high-resolution structural variants in nanopore long reads. *Nat Methods*. 2018 Jun;15(6):455-460. doi: 10.1038/s41592-018-0002-6. Epub 2018 Apr 30.
259. F Menghi, FP Barthel, V Yadav, M Tang, B Ji, ZH Tang, GW Carter, YJ Ruan, R Scully, RGW Verhaak, Jonkers J, **Liu ET**. The Tandem Duplicator Phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations. *Cancer Cell*. 2018 Jun 29. pii: S1535-6108(18)30265-4.
260. Inselmann S, Wang Y, Saussele S, Fritz L, Schütz C, Huber M, Liebler S, Ernst T, Cai D, Botschek S, Brendel CA, Calogero R, Pavlinic D, Benes V, **Liu ET**, Neubauer A, Hochhaus A, Burchert A.

Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia. *Cancer Res.* 2018 Aug 30. pii: canres.1477.2018.

261. Kim H, Kumar P, Menghi F, Noorbakhsh J, Cerveira E, Ryan M, Zhu Q, Ananda G, George J, Chen HC, Mockus S, Zhang C, Yang Y, Keck J, Karuturi RKM, Bult CJ, Lee C, **Liu ET**, Chuang JH. High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts. *Sci Rep.* 2018 Dec 18;8(1):17937. doi: 10.1038/s41598-018-36184-8.
262. Wang P, Tang Z, Lee B, Zhu JJ, Cai L, Szalaj P, Tian SZ, Zheng M, Plewczynski D, Ruan X, Liu ET, Wei CL, Ruan Y. Chromatin topology reorganization and transcription repression by PML-RAR α in acute promyeloid leukemia. *Genome Biol.* 2020 May 11;21(1):110. doi: 10.1186/s13059-020-02030-2.

Reviews, Books Chapters:

263. Benz CC, **Liu E** (Editors). Oncogenes in the monograph series Cancer Research and Treatment. Kluwer 1989.
264. Liu ET. "The Role of ras Gene Mutations in Myeloproliferative Disorders." In Myeloproliferative Disorders. Clinics in Laboratory Medicine. W.B. Saunders Co, pp.797-807, 1989.
265. Liu, ET. "Ras Gene Mutations in Acute Myelogenous Leukemia. " In Acute Myelogenous Leukemia: Progress and Controversies. UCLA Symposia on Molecular and Cellular Biology, Vol. 134. pp. 107-116. Wiley-Liss, 1990.
266. Benz CC, **Liu ET** (Editors). Oncogenes II in the monograph series, Cancer Research and Treatment. Kluwer 1993. Authored Chapters: Oncogenes and Tumor-Suppressor Genes, pp. 1-15.
267. **Liu ET**, He M, Rajgopal U. Differential Polymerase Chain Reaction in the Analysis of Gene Dosage. *Seminars in Cancer Biology* 4:47-58, 1993. Editor: Kari Alitalo.
268. Liu ET. From the Molecule to Public Health. Editorial; *New England J Med*, 329:2028-2029 (1993).
269. Liu ET. Oncogenes, Breast Cancer, and Chemoprevention. *J. Cellular Biochemistry, J. of Cellular Biochemistry* 17G:161-166, (1993).
270. Hulka BS, **Liu ET**, Lininger RA. Steroid Hormones and Risk of Breast Cancer. *Cancer* 74(3):1111-1124, 1994.
271. Weber B, Giusti RM, **Liu ET**. Developing Strategies for Intervention and Prevention in Hereditary Breast Cancer. *JNCI*, (17)99-102, 1995.
272. Liu E, Nuzum C. Molecular sleuthing: tracking ovarian cancer progression. *J Natl Cancer Inst* 87(15):1099-1101, 1995.
273. Berry DA, Thor A, Cirrincione C, Edgerton S, Muss H, Marks J, **Liu E**, Wood W, Budman D, Perloff M, Peters W and Henderson IC. Scientific inference and predictions; multiplicities and convincing stores: A case study in breast cancer therapy. In *Bayesian Statistics*, JM Bernardo, JO Berger, AP Dawin and AFM Smith eds. Oxford University Press, Vol. 5, pp. 45-67, 1996.
274. Sadler T. W.; **Liu E. T.**; Augustine K. A. "Targeted gene disruptions as models of abnormal development", in Handbook of experimental pharmacology Drug toxicity in embryonic development I: advances in understanding mechanisms of birth defects: morphogenesis and processes at risk 124:325-340 (1997) Springer, Berlin

275. Newman B, Liu, ET. Perspective on BRCA1. *Breast Disease* 10 (1,2): 3-10, 1998.
276. Liu ET. The uncoupling of race and cancer genetics. *Cancer Suppl.* 83: 765-1769, 1998.
277. Zujewski J, Liu ET. The 1998 St. Gallen's Consensus Conference: an assessment. *J Natl Cancer Inst.* 90(21):1587-1589, 1998.
278. Liu ET. *Oncogenes and Suppressor Genes: Genetic Control of Cancer.* Cecil Textbook of Medicine (21st Edition) Editors: L. Goldman, and J. Claude Bennett, W.B. Saunders, 1999.
279. Liu ET. Molecular Markers in Cancer Therapy: Evolution of a Concept. In *Molecular Basis of Cancer* (2nd Edition) Editors, Mendelsohn J, Howley P, Israel M, Liotta L. W.B. Saunders, 1999.
280. Liu ET. Cancer biology (Editorial overview). In *Current Opinion in Oncology*, 11:49, 1999.
281. Bishop PC, Bates SE, **Liu ET.** Molecular Targets for Breast Cancer Therapy. *Seminars in Breast Diseases* (1999)
282. **Liu ET,** Nealon E, Klausner R. Breast Cancer Advocacy: Perspective from the NCI. *Breast Disease* (1999)
283. Johnston PG, Daly PA, **Liu E.** The NCI All Ireland Cancer Conference. *Oncologist.* 1999;4(4):275-277.
284. Liu ET, Breast Cancer Research: Where we are and where we should go. *Breast Cancer Research* (2000)2(2):73-6
285. Johnston PG, Daly PA, Liu E, The NCI All Ireland Cancer Conference. *Oncologist* 4(4):275-277, (1999).
286. Liotta, LA and **Liu, ET.** "Essentials of Molecular Biology: Basic Principles" in Cancer Principles and Practice of Oncology (Sixth Edition). Editors: DeVita, Hellman and Rosenberg. Williams and Wilkins, Philadelphia PA (2000)
287. Paik S, **Liu ET.** HER2 as a predictor of therapeutic response in breast cancer. In *HER-2*, Breast Disease. Ed. Yosef Yarden, Edison Liu. IOS Press (2000).
288. Järvinen TAH, **Liu ET.** Effects of HER-2/neu on chemosensitivity of tumor cells. *Drug Resist Updat.* 3(6):319-324 (2000).
289. Gardner K, **Liu ET.** BRCA1 function in T lymphocytes: a cellular specificity of a different kind. *Breast Cancer Res.* 3(1):11-3 (2001).
290. **Liu ET,** Sotiriou C. Defining the Galaxy of Gene Expression in Breast Cancer. *Breast Cancer Res.* 4(4):141-4 (2002).
291. Miller, LD, Long PM, Wong L, Mukherjee S, McShane LM, and **Liu ET.** Optimal gene expression analysis by microarrays. *Cancer Cell* 2:353-361 (2002).
292. **Liu ET,** Classifications of Cancers by Expression Profiling. *Current Opinion in Genetics & Development* 13(1):97-103, 2003.
293. **Liu ET.** Molecular OncoDiagnostics: where we are and where we need to go. *J Clin Oncol.* 21(11):2052-5, 2003.
294. Jarvinen TA, **Liu ET.** HER-2/neu and topoisomerase IIalpha in breast cancer. *Breast Cancer Res Treat.* 78(3):299-311, 2003.

295. Jarvinen TA, **Liu ET**. HER-2/neu and topoisomerase II alpha--simultaneous drug targets in cancer. *Comb Chem High Throughput Screen*. 6(5):455-70, 2003.
296. **Liu ET**. *Oncogenes and Suppressor Genes: Genetic Control of Cancer*. Cecil Textbook of Medicine (22st Edition) Editors: L. Goldman, and J. Claude Bennett, W.B. Saunders, 2003.
297. Ruan YJ, LeBer P, Ng HH, **Liu ET**. Interrogating the transcriptome, *Trends in Biotechnology*. 22(1):23-30 (2004).
298. Miller L, **Liu ET**. Expression profiling and breast cancer biology. *Breast Dis*. 19:29-34.(2004)
299. **Liu ET**. Representational oligonucleotide microarray analysis (ROMA) in pharmacogenomics. *Pharmacogenomics J*. 2004;4(2):74-6.
300. **Liu ET**, Karuturi KR. Microarrays and Clinical Medicine (Invited Perspective). *New England Journal of Medicine*, 350(16):1595-7. (2004)
301. **Liu ET**. Expression genomics and cancer biology. *Pharmacogenomics*. 5(8):1117-28. (2004)
302. **Liu ET**. Genomic technologies and the interrogation of the transcriptome. *Mech Ageing Dev*. 126(1):153-9. (2005)
303. **Liu ET**. Mechanism-derived gene expression signatures and predictive biomarkers in clinical oncology. *Proc Natl Acad Sci U S A*. 102(10):3531-2. (2005)
304. **Liu ET**. Integrative biology and systems biology. *Mol Syst Biol*. 1:2005.0004 (2005). Epub 2005 Mar 29.
305. **Liu ET**. Expression genomics and drug development: towards predictive pharmacology. *Brief Functional Genomic Proteomics*. 3(4):303-21 (2005).
306. **Liu ET**. Systems biology, integrative biology, predictive biology. *Cell*. 121(4):505-6. (2005)
307. **Liu ET**. New technologies for high-throughput analysis. *Pharmacogenomics*. Jul;6(5):469-71. (2005)
308. **Liu ET**, Kutznesov VA, Miller LD. In the pursuit of complexity: Systems medicine in cancer biology. *Cancer Cell* 9(4):245-7. (2006)
309. Jarvinen TA, **Liu ET**. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase II alpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer. *Curr Cancer Drug Targets*. 6(7):579-602. (2006)
310. Miller LD, **Liu ET** Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. *Breast Cancer Res*. 2007 Mar 26;9(2):206 [Epub ahead of print]
311. **Liu ET**, Lemberger T. Higher order structure in the cancer transcriptome and systems medicine. *Mol Syst Biol*. 2007;3:94. Epub 2007 Mar 13.
312. Petretto E, **Liu ET**, Aitman TJ. A gene harvest revealing the archeology and complexity of human disease. *Nat Genet*. 2007 Nov;39(11):1299-301.
313. **Liu ET**. Perspectives: Stromal Effects in Breast Cancer. *N Engl J Med* 357(25):2537-2538. December 20, 2007.
314. **Liu ET**. Functional genomics of cancer. *Curr Opin Genet Dev*. Jun;18(3):251-6. Epub 2008 Aug 28.

315. Chow TF, Chia KS, Hall P., and **Liu ET**. "Biobanking in the Post-Genome Era". Chapter 24, pg. 284-298, in Genomic and Personalized Medicine. Edited by Huntington F. Willard and Geoffrey S. Ginsburg. Elsevier and Academic Press 2009.
316. **Liu ET**. Integrative biology - a strategy for systems biomedicine. Nat Rev Genet. 2009 Jan;10(1):64-8.
317. Fullwood MJ, Wei CL, **Liu ET**, Ruan Y. Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res. 2009 Apr;19(4):521-32.
318. **Liu ET**. The Human Genome Organisation (HUGO). Hugo J. 2009 Dec;3(1-4):3-4.
319. Kumar D, **Liu ET**. The emergence of 'The HUGO Journal'. Hugo J. 2009Dec;3(1-4):1-2. Epub 2010 Apr 10.
320. International Cancer Genome Consortium (member). International network of cancer genome projects. Nature. 2010 Apr 15;464(7291):993-8.
321. Reekie K, Metspalu A, Chanock SJ, **Liu ET**, Mardis ER, Scherer SW, Kwok PY, Brookes AJ. HGV2009 meeting: bigger and better studies provide more answers and more questions. Hum Mutat. 2010 Jul;31(7):886-8. PubMed PMID: 20506253.
322. **Liu ET**, Pott S, Huss M. Q&A: ChIP-seq technologies and the study of gene regulation. BMC Biol. 2010 May 14;8:56.
323. Charmaine KM Chan and **Edison T Liu**. Chapter 2: "The Impact of the Bioethics Advisory Committee on the Research Community in Singapore" in Bioethics in Singapore: The Ethical Microcosm. Edited by John M Elliott, W Calvin Ho, & Sylvia S N Lim. World Scientific Press, 2010.
324. Diamandis EP, Hudson T, Kallioniemi O, **Liu ET**, López-Otín C. Cancer Genomes. Clin Chem. 2010 Nov;56(11):1660-4.
325. Kedes L, **Liu ET**. The Archon Genomics X PRIZE for whole human genome sequencing. Nat Genet. 2010 Nov;42(11):917-8.
326. Inaki K, **Liu ET**. Structural mutations in cancer: mechanistic and functional insights. Trends Genet. 2012 Nov;28(11):550-9. Epub 2012 Aug 17.2012
327. **Liu, ET**. Grappling with Cancer (Editorial). Science 339: 1493 (2013)
328. **Liu ET**, Johnston PG. Personalized medicine: does the molecular suit fit? Oncologist. 2013 Jun;18(6):653-4.311
329. Sundberg JP, Roopenian DC, **Liu ET**, Schofield PN. The Cinderella Effect: Searching for the Best Fit between Mouse Models and Human Diseases. J Invest Dermatol. 2013 Jun 27.
330. **Liu, ET**. *Science Diplomacy: New Day or False Dawn?* Chapter 11: Global Health Research Diplomacy. 2014

331. **Liu ET**, Bult CJ, Shultz LD. Patient-Derived Tumor Xenografts: Why Now? JAMA Oncol. 2016 Apr 7. doi: 10.1001/jamaoncol.2016.0193. [Epub ahead of print]
332. **Liu ET**, Bolcun-Filas E, Grass DS, Lutz C, Murray S, Shultz L, Rosenthal N. Of mice and CRISPR: The post-CRISPR future of the mouse as a model system for the human condition. EMBO Rep. 2017 Feb;18(2):187-193.
333. Olson B, Li Y, Lin Y, **Liu ET**, Patnaik A. Mouse Models for Cancer Immunotherapy Research. Cancer Discov. 2018 Oct 11. doi: 10.1158/2159-8290.CD-18-0044. [Epub ahead of print]
334. Liu ET, Mockus SM Tumor Origins Through Genomic Profiles. JAMA Oncol. 2019 Nov 14. doi: 10.1001/jamaoncol.2019.3981. Online ahead of print.PMID: 31725824

Books:

335. Burck K, Liu E, Larrick J. Oncogenes: An Introduction to the Concept of Cancer Genes. Springer-Verlag, 293 pages, 1988. (Translated into Japanese 1990)
336. Terry Kaan and Edison T Liu (editors). Life Sciences: Law and Ethics - Recent Developments in Singapore. Singapore Academy of Law (Academy Publishing) 2007
337. Liu ET, Lauffenberger DA. Systems Biomedicine: Concepts and Perspectives. Elsevier and Academic Press. 2009 (Chinese Edition 2011)

Chapter 1: Foundations for Systems Biomedicine: an Introduction. *Edison T. Liu*
Chapter 2: Genomic Technologies for Systems Biology. *Edison T. Liu, Sanket Goel, Kartiki Desai, and Mathijs Voorhoeve*
Chapter 4: Cellular Regulatory Networks: *Brian A. Joughin , Edwin Cheung , R. Krishna Murthy, Karuturi , Julio Saez-Rodriguez , Douglas A. Lauffenburger and Edison T. Liu*
Chapter 16: Systems Pharmacology in Cancer. *Qiang Yu and Edison T. Liu*
Chapter 18: Quantitative Biology and Clinical Trials: a Perspective. *Robert A. Harrington and Edison T. Liu*

Non-Science publications:

- “Testing for the virus: Hopes - and realities.” Edison Liu and Ai Ee Ling April 16, 2003. Straits Times, Singapore. Article explaining the development of diagnostics for SARS
- “Small Singapore has much to be proud of”. Edison Liu. August 5, 2003. Straits Times, Singapore. Op Ed piece
- “Crime and Punishment?” Edison Liu. September 30, 2003. Straits Times, Singapore. Op Ed piece.
- “Can it happen in Singapore?” Edison Liu. December 30, 2005. Straits Times, Singapore (national newspaper). Op Ed on Suk Woo Hwang
- “The world is beginning to look like Singapore.” Edison T. Liu . March 2005. Straits Times, Singapore (national newspaper). Op Ed on Singapore’s national culture

- “Going Forward In Stem Cell Research”. Edison T Liu and Ng Huck Hui . December 10, 2008. Straits Times, Singapore (national newspaper). Informational article on stem cell research for the national newspaper.
- “Bioethics, clinical research, and patient information.” Edison Liu June 2006. Straits Times, Singapore (national newspaper). Informational article on bioethics for the public.
- “This is the most exciting place to do science” Edison Liu. March 11, 2007. Straits Times, Singapore (national newspaper). Op Ed on biological sciences in Singapore.
- “Why Setting the Right Rules for Health Care Products is Critical”. Edison Liu & John C. Lim. September 1, 2007. Straits Times, Singapore (national newspaper). Article on health regulation in Singapore.
- BioColumn: “What is next in biotechnology?” Edison T. Liu. March-April 2007. Biospectrum (Biotechnology industry journal)
- BioColumn: “Social arbitrage” Edison T Liu. April 2007. Biospectrum (Biotechnology industry journal).
- BioColumn: “Combinatorial drug therapy and systems biology”. Edison T Liu. July-August 2007. Biospectrum (Biotechnology industry journal)
- BioColumn: “Sequencing of Individual Genomes”. Edison T Liu & Sharon CC Chiang. September 2007. Biospectrum (Biotechnology industry journal)
- BioColumn: ”Ecology for Success in the Biomedical Sector”. Edison T Liu. November 2007. Biospectrum (Biotechnology industry journal)
- BioColumn: ”Innovative Regulator: the Health Sciences Authority of Singapore”. Edison T Liu. January 2008. Biospectrum (Biotechnology industry journal)
- BioColumn: “Changing national health outcomes, telecommunications in medicine” Edison T. Liu. March 2008. Biospectrum (Biotechnology industry journal).
- BioColumn: “Contribute to the future of medicine” Edison T. Liu. April 2008. Biospectrum (Biotechnology industry journal).
- BioColumn: “What is wrong with Asian biotech” Edison T. Liu. June 2008. Biospectrum (Biotechnology industry journal).
- Book Review “The Language of Life: DNA and the Revolution in Personalized Medicine” by Francis S. Collins Harper, 2010. Reviewed by Edison T Liu. Nature Medicine. 16 (1):24 (2010)

Trainees: (year of completion, year of follow-up)

Post-doctoral Fellows:

Roy A. Frye, M.D., Ph.D. (1991)
 (ACS Career Development Award)
 Current Position (1997): Assist. Prof.
 University of Pittsburgh

Andreas Neubauer, M.D. (1990)
(Deutsche Forschungsgemeinschaft)
Current Position (2010): Chief
Hematology,
University of Marburg, Germany

Peter Effert, M.D. (1991)
(Deutsche Forschungsgemeinschaft)
Current Position (1995): Assistenzarzt,
Heinrich Heine Universität,
Dusseldorf, Germany.

Eleni Levedakou, Ph.D. (1993)
(Susan Komen Foundation Fellowship)
Current Position (2006): Research
Scientist,
Department of Neurology, University of Chicago

Gwen Spizz, Ph.D. (1994)
(Cancer Center Training Grant)
Current Position (1996): Research
Associate,
Howard Hughes Medical Institute,
Duke University Medical Center, N.C.

Man Chang, Ph.D. (1995)
(Cancer Center Training Grant)
Current Position (1996): Post-doctoral
fellow
Wayne State University, MI.

Yu Li, M.D. Ph.D. (1996)
Current Position (2007): Assistant Professor
Pathology, University of Virginia Charlottesville

Wendall Yarbrough, M.D. (1996)
(K08 Award, UNC Chapel Hill)
Current Position (2015):
Professor and Chief Otolaryngology, Yale University

William Cance III, M.D. (1996)
(K08 Award, UNC Chapel Hill)
Current Position (2009): Chief, Department of Surgery,
Roswell Park Cancer Institute, New York .

Yih-Woei Fridell, Ph.D. (2000)
(Senior Staff Fellow, NCI)
Current Position (2004):

Assistant Professor, University of Conn.
(CT).

Qinbin Guo, Ph.D. (2000)
(Senior Staff Fellow, NCI)
Current Position (2008):
Program Director, National Institute of Ageing
NIH, Bethesda, MD

Lisa Gangi, Ph.D. (2000)
(Senior Staff Fellow, NCI)
Current Position (2002):
Director, Microarray Facility
NCI, Frederick (MD)

Jacy Villa, M.D. (2000)
(Senior Staff Fellow, NCI)
Current Position (2000):
Private Practice Oncology, Florida

Bruno Fang, M.D. (2000)
(Senior Staff Fellow, NCI)
Current Position (2000):
Private Practice Oncology, New Jersey

Qiang Yu, Ph.D. (2002)
Current Position (2010)
Group Leader, Genome Institute of Singapore

Olga Aprelikova, Ph.D. (2002)
Current Position (2010)
Staff Scientist, NCI, NIH

Ting Qui, Ph.D.
Current Position (2010)
Staff Scientist, NCI, NIH

Chandramouli Gadesetti, Ph.D. (2002)
Current Position (2006)
Research Scientist, NCI (USA)

Amir Jazaeri, M.D. (2002: NCI-SGO Fellowship)
Current Position (2010)
Assistant Professor, Obstetrics & Gynecology
University of Virginia at Charlottesville

Mei He, M.D. (2002)
Current Position (2016)

Staff Scientist, NCI, NIH

Chin Yo LIN, Ph.D (2005)

Current Position:

Assistant Professor

University of Houston (2010)

Roy Joseph, Ph.D. (2008)

Current Position:

Senior Scientist, Lilly Singapore Center for Drug Development
(2009)

Sabry Mohammed Hamza, Ph.D. (2009)

Current Position:

Group Leader, Schering Plough Research Institute
(2009)

Francesca Menghi, Ph.D. (2011)

Current Position:

Research Scientist, The Jackson Laboratory (2018)

Xing Yi Woo, Ph.D. (2012)

Current Position:

Consultant Computational Scientist, The Jackson Laboratory

Koichiro Inaki, Ph.D. (2013)

Current Position:

Senior Scientist, Functional Genomics and Proteomics
Research Group, Discovery Science and Technology
Department, Daiichi Sankyo RD. Japan (2015)

Joel Wagner, Ph.D. (2015)

American Cancer Society Fellow

Current Position:

Senior Computational Scientist, Novartis Oncology (2015)

Pooja Kumar, Ph.D. (2020)

Current Position: Associate Research Scientist,
The Jackson Laboratory

Richa Singh, Ph.D. (2018)

Mayuko Furuta, Ph.D. (2020)

Jackson Laboratory Scholar

Current Position: Associate Research Scientist,
The Jackson Laboratory

Graduate Students:

Barry Kitch (Medicine, 1992)
(N.I.H. Medical Student Preceptor Program)
Current Position (2007): Assistant Professor,
Brigham and Women's Hospital, Center For Chest Diseases

John O'Bryan (Ph.D., Genetics, 1992)
(Howard Hughes Predoctoral Fellowship)
Current Position (2016):
Associate Professor, University of Illinois, Chicago

Koon Siew Lai (Ph.D., Biology, 1996)
Current Position (1999):
Assistant Professor, Johns Hopkins University/National
University of Singapore, Clinical Pathology Program.

Patrick McCloskey, (Ph.D. Genetics, 1996)
Current Position (2007):
Assistant Director, Office of Corporate Liaison and Technology
Development, Rutgers University

Eyal Attar, (M.D. UNC Chapel Hill. Howard Hughes Medical
Fellowship, 1996)
Current Position (2007):
Assistant Professor, Medicine, Mass General Hospital. Boston,
MA.

Rolf Craven, (Ph.D. Genetics, 1995; USARMC Breast Cancer
pre-doctoral fellow)
Current Position (2006):
Assistant Professor, Molecular and Biomedical Pharmacology,
University of Kentucky

Carol Carter, (Ph.D. Genetics, 2001)
Current Position (2003):
Post Doctoral Fellow, NCI

Subashini Chandrasekaran (Ph.D., Genetics, 2001)
Current Position (2010)
Staff Fellow, Duke University

Lance Miller, (Ph.D. Genetics 2001)
Current Position (2015) Associate Professor, Cancer Biology,
Wake Forest University Medical School

Bangarusamy Dhinoth Kumar (Ph.D. Biochemistry, 2008).
Current Position: Assistant Professor, King Abdullah
University of Science and Technology. Saudi Arabia.

Yew Kok LEE (Ph.D. National Graduate School for Integrative Sciences, NUS; 2009). Current Position (2014) computational biologist, National University of Singapore

Tze Howe CHARN. (Ph.D. University of Illinois Champaign Urbana; 2010). Current Position (2016) Senior Scientist Fluidigm, California

Wendy SOON. (Ph.D. National University of Singapore; 2010). Current position (2016) Director, Sequencing Facility, Genome Institute of Singapore

Yi Fang LEE (Ph.D. Nanyang Technology University 2011). Current Position: Senior Scientist, ClearBridge Biomedics, Singapore (2016)

Say Li KONG (Ph.D. National University of Singapore 2012). Current Position: Post-doctoral position with Dr. Bing Lim, Genome Institute of Singapore (2014)

Gaye Saginc (Ph.D., National University of Singapore, 2015). Current Position: Post-doctoral Fellow with Dr. Rune Linding, Copenhagen (2016).

Faranak Ghazi Sherbaf (Ph.D. Post-Doctoral fellow, National University of Singapore; 2016)

Research Grants:**Current Research Support:**

2 P30 CA034196-34, Liu (PI)
NIH/NCI

04/01/20 – 03/28/25

Cancer Center Support (Core) Grant

The objective of this grant is to support cancer research at The Jackson Laboratory. This has been a continuously funded grants since 1983. Our impact score at the renewal in 2019 was 20 with an Outstanding descriptor.

The Jackson Laboratory Cancer Center provides a unique concentration of genetic and genomic expertise focusing on applications of murine model systems and systems genomics in addressing cancer questions.

Role: Principal Investigator

19-036-ASP

Mark Foundation Cancer Fund Liu (PI)

11/01/19-04/30/22

Dissecting the Genetic Control of Response to Immune Checkpoint Inhibitors in Cancer

This grant is to assess the effect of host genetics on immune-oncology agent efficacy using genetically diverse mice.

Role: Principal Investigator

1R01CA255705-01 Liu (PI)

12/01/20-11/30/25

NCI/NIH

Genomic Biology of the Tandem Duplicator Phenotype in Mouse and Human Cancers

This grant supports our work on determining the origins and evolution of models of breast cancer with the tandem duplicator phenotype.

Role: Principal Investigator

ALFOND-FY20ETL, Liu (PI)

10/1/2020 - 9/30/2025

Harold Alfond Foundation

Maine Cancer Genomics Initiative 2.0

The goal of this project is to provide cancer genomics diagnostics to approximately 3200 Maine patients over 5 years.

Role: Principal Investigator

Completed Research Support:

BC160172P1 Liu (PI) Scully (co-PI)

03/01/17-02/29/21

DoD Breast Cancer Research Program, Breakthrough Award

This grant supports the investigation of the tandem duplicator phenotype as a new chromotype in triple negative breast cancer with sensitivity to cisplatin.

Role: Co-Principal Investigator

1 U10 CA180944-01 Baker, Liu, Tuveson (PI)

06/12/14-02/28/19

NIH/NCI

SWOG Network Group Integrated Translational Science Center

The Jackson Laboratory (JAX) is a full partner in the National Clinical Trials Network Group Integrated Translational Science Center. Dr. Liu will work collaboratively with the co-PIs of this project as well as leaders and members of the Network Group and NCI program officials to promote translational research at JAX and integrate the outcomes of translational pilots into late phase clinical trials. Together with the co-PIs, JAX faculty and staff will organize an annual meeting at JAX for Network group members to educate basic, translational and clinical researchers about key clinical challenges and translational research opportunities to address them.

Role: Principal Investigator

51006091 Liu (PI)

09/01/07-08/31/13

Howard Hughes Medical Institute

Precollege Science Education Initiative for Biomedical Research Institutes

The major goal of this project is to grow and diversify mentorship program participation by high school students and science teachers.

Role: Principal Investigator

MTAF2012 Liu (PI)

07/01/12-12/31/12

Maine Technology Institute

Maine Regional Flow Cytometry Consortium (MRFCC)

Role: Principal Investigator

MBRB2012 Liu (PI)

03/05/12-06/30/12

Maine Technology Institute

Expanding JAX Sequencing and Data Analysis Pipelines Beyond Mouse

Role: Principal Investigator

RFA-CA-07-001 Liu (PI)

05/15/07-05/14/10

NIH/NCI

Pair-end-ditag technologies for the complete annotation of fusion genes

This grant is to develop pair-end-tagging technologies for the discovery of functional translocations in cancer.

Role: Principal Investigator

R01 HG003521-01 (ENCODE) Ruan (PI)

09/01/04 – 06/30/07

Ditag technologies for complete transcriptome annotation

National Institutes of Health

This grant is to develop new technologies for transcriptome annotation.

Role: Co-Investigator

Susan G Komen Foundation Hall (PI)

06/01/04 – 05/31/06

Genetic and environmental determinants of postmenopausal breast cancer.

Role: Co-Principal Investigator

FP6-2004-LIFESCIHEALTH-5 (CRESCENDO) 10/01/04 – 09/30/09

Consortium for Research into Nuclear Receptors in Development and Aging

European Commission

Role: Partner and co-Principal Investigator

CA-98-013 Green (PI)

10/1999-09/2002

NIH/NCI

Mouse Model for Human Cancer Consortium: NCI Mammary Mouse Collective

The NCI Mouse Mammary Collective is one of 19 members of a national consortium to construct and to study mouse models for human cancers

Role: Co-Principal Investigator

1 U01 CA88175-01 Boyd (PI)

09/2000-09/2004

NIH/NCI

NCI Director's Challenge Grants: Expression analysis of ovarian cancers

This project is to determine whether the array profiles from the GOG ovarian tumor bank can be correlated with clinical outcome.

Role: Co-Principal Investigator

Leukemia Research:

RO1 CA49240-06 Liu (PI)

07/01/96-06/30/00

NIH/NCI

Biology of the AXL Receptor Tyrosine Kinase in Breast Cancer

This project examines the role of axl, a receptor tyrosine kinases, in human breast cancer.

Role: Principal Investigator

Leukemia Society Scholars Award Liu (PI)

12/31/91-12/30/96

Molecular Genetics of Leukemogenesis

This project examines the molecular lesions involved in human leukemogenesis.

Role: Principal Investigator

Breast Cancer Research:

5 U10 CA37027-11 Liu (PI)

05/01/93-04/31/98

NIH/NCI

Cancer and Leukemia Group B

This grant is to identify the ligand for the axl oncogene

Role: Principal Investigator

P50 CA58223-03 Liu (PI)

10/01/92-09/30/00

NIH

Specialized Program of Research Excellence (SPORE) in Breast Cancer

This is one of six SPOREs awarded for the comprehensive study of breast cancer.

Role: Principal Investigator

1 U01 CA64061-01 Liu (PI)

06/01/94-06/30/99

NIH

HER-2 Oncogene and Response to Dose Intensive Therapy.

This grant is to study the interaction between HER-2 overexpression and amplification and dose intensive adjuvant chemotherapy.

Role: Principal Investigator

Pagano (PI)

06/01/94-05/31/99

NIH/NCI

Cancer Center Core Support Grant - Program Leader in Breast Cancer

Provides salary support as program leader in breast cancer research for the Cancer Center.

Role: Program Leader

Liu (PI)

08/01/96-07/31/00

USARMC/DOD

Protein Kinases in Breast Cancer

This grant is to study two kinases rak and cdk7 in breast cancer biology.

Role: Principal Investigator

Molecular Epidemiology:

RFP. N01-ES-15327 Liu (PI)

09/30/91-09/29/96

NIH/NIEHS

Oncogene Analysis for Epidemiologic Studies

This contract is to study the role of oncogene mutations in the cancer epidemiology of bladder and lung cancer.

Role: Principal Investigator